CAFFEINE is a central nervous system (CNS) stimulant of the
methylxanthine class . It is the world's most widely consumed
psychoactive drug . Unlike many other psychoactive substances, it is
legal and unregulated in nearly all parts of the world. There are
several known mechanisms of action to explain the effects of caffeine.
The most prominent is that it reversibly blocks the action of
adenosine on its receptor and consequently prevents the onset of
drowsiness induced by adenosine.
Caffeine also stimulates certain
portions of the autonomic nervous system .
Caffeine is a bitter, white crystalline purine , a methylxanthine
alkaloid , and is chemically related to the adenine and guanine bases
of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). It is found
in the seeds, nuts, or leaves of a number of plants native to South
America and East Asia and helps to protect them against predator
insects and to prevent germination of nearby seeds. The most well
known source of caffeine is the coffee bean , a misnomer for the seed
Beverages containing caffeine are ingested to
relieve or prevent drowsiness and to improve performance. To make
these drinks, caffeine is extracted by steeping the plant product in
water, a process called infusion . Caffeine-containing drinks, such as
coffee , tea , and cola , are very popular; in 2005, 90% of North
American adults consumed caffeine daily.
Caffeine can have both positive and negative health effects. It can
treat and prevent the premature infant breathing disorders
bronchopulmonary dysplasia of prematurity and apnea of prematurity .
Caffeine citrate is on the
WHO Model List of Essential Medicines . It
may confer a modest protective effect against some diseases,
including Parkinson\'s disease . Some people experience insomnia or
sleep disruption if they consume caffeine, especially during the
evening hours, but others show little disturbance. Evidence of a risk
during pregnancy is equivocal; some authorities recommend that
pregnant women limit consumption to the equivalent of two cups of
coffee per day or less.
Caffeine can produce a mild form of drug
dependence – associated with withdrawal symptoms such as sleepiness,
headache, and irritability – when an individual stops using caffeine
after repeated daily intake. Tolerance to the autonomic effects of
increased blood pressure and heart rate, and increased urine output,
develops with chronic use (i.e., these symptoms become less pronounced
or do not occur following consistent use).
Caffeine is classified by the US
Food and Drug Administration
Food and Drug Administration as
"generally recognized as safe " (GRAS). Toxic doses, over 10 grams per
day for an adult, are much higher than typical doses of under 500
milligrams per day. A cup of coffee contains 80–175 mg of caffeine,
depending on what "bean" (seed) is used and how it is prepared (e.g.
drip , percolation , or espresso ). Thus it requires roughly 50–100
ordinary cups of coffee to reach a lethal dose. However pure powdered
caffeine, which is available as a dietary supplement , can be lethal
in tablespoon-sized amounts.
* 1 Use
* 1.1 Medical
* 1.2 Enhancing performance
* 1.2.1 Cognitive
* 1.2.2 Physical
* 1.3 Specific populations
* 1.3.1 Adults
* 1.3.2 Children
* 1.3.3 Adolescents
* 1.3.4 Pregnancy and breastfeeding
* 2 Side effects
* 2.1 Physical
* 2.2 Psychological
* 2.3 Reinforcement disorders
* 2.3.2 Dependence and withdrawal
* 2.4 Risk of other diseases
* 3 Overdose
* 4 Interactions
* 4.3 Oral birth control
* 4.4 Medications
* 5 Pharmacology
* 5.1 Pharmacodynamics
* 5.1.1 Receptor and ion channel targets
* 188.8.131.52 Effects on striatal dopamine
* 5.1.3 Off-target effects
* 6 Chemistry
* 6.1 Synthesis
* 6.3 Detection in body fluids
* 6.4 Analogs
* 7 Natural occurrence
* 8 Products
* 8.1.3 Soft drinks and energy drinks
* 8.1.4 Other beverages
* 8.3 Tablets
* 8.4 Other oral products
* 8.5 Inhalants
* 8.6 Combinations with other drugs
* 9 History
* 9.1 Discovery and spread of use
* 9.2 Chemical identification, isolation, and synthesis
* 9.3 Historic regulations
* 10 Society and culture
* 10.1 Regulations
* 10.2 Consumption
* 10.3 Religions
* 11 Other organisms
* 12 Research
* 13 See also
* 14 References
* 15 Bibliography
* 16 External links
Caffeine is used in:
Bronchopulmonary dysplasia in premature infants for both
prevention and treatment. It may improve weight gain during therapy
and reduce the incidence of cerebral palsy as well as reduce language
and cognitive delay. On the other hand, subtle long-term side
effects are possible.
Apnea of prematurity as a primary treatment, but not prevention.
Orthostatic hypotension treatment.
Caffeine is a central nervous system stimulant that reduces fatigue
and drowsiness . At normal doses, caffeine has variable effects on
learning and memory, but it generally improves reaction time ,
wakefulness , concentration, and motor coordination . The amount of
caffeine needed to produce these effects varies from person to person,
depending on body size and degree of tolerance. The desired effects
arise approximately one hour after consumption, and the desired
effects of a moderate dose usually subside after about three or four
Caffeine can delay or prevent sleep , and improves task performance
during sleep deprivation. Shift workers who use caffeine make fewer
mistakes due to drowsiness.
A systematic review and meta-analysis from 2014 found that concurrent
L-theanine use has synergistic psychoactive effects that
promote alertness, attention, and task switching ; these effects are
most pronounced during the first hour post-dose.
Caffeine is a proven ergogenic aid in humans.
athletic performance in aerobic (especially endurance sports ) and
anaerobic conditions. Moderate doses of caffeine (around 5 mg/kg )
can improve sprint performance, cycling and running time trial
performance, endurance (i.e., it delays the onset of muscle fatigue
and central fatigue ), and cycling power output.
For the general population of healthy adults,
Health Canada advises a
daily intake of no more than 400 mg.
In healthy children, caffeine intake produces effects that are
"modest and typically innocuous". There is no evidence that coffee
stunts a child's growth. For children age 12 and under, Health Canada
recommends a maximum daily caffeine intake of no more than 2.5
milligrams per kilogram of body weight. Based on average body weights
of children, this translates to the following age-based intake limits:
MAXIMUM RECOMMENDED DAILY CAFFEINE INTAKE
45 mg (slightly more than in 12 oz of a typical soft drink)
85 mg (about ½ cup of coffee)
Health Canada has not developed advice for adolescents because of
insufficient data. However, they suggest that daily caffeine intake
for this age group be no more than 2.5 mg/kg body weight. This is
because the maximum adult caffeine dose may not be appropriate for
light weight adolescents or for younger adolescents who are still
growing. The daily dose of 2.5 mg/kg body weight would not cause
adverse health effects in the majority of adolescent caffeine
consumers. This is a conservative suggestion since older and heavier
weight adolescents may be able to consume adult doses of caffeine
without suffering adverse effects.
Pregnancy And Breastfeeding
Food Standards Agency has recommended that pregnant women
should limit their caffeine intake, out of prudence, to less than 200
mg of caffeine a day – the equivalent of two cups of instant coffee,
or one and a half to two cups of fresh coffee. The American Congress
of Obstetricians and Gynecologists (ACOG) concluded in 2010 that
caffeine consumption is safe up to 200 mg per day in pregnant women.
For women who breastfeed, are pregnant, or may become pregnant, Health
Canada recommends a maximum daily caffeine intake of no more than 300
mg, or a little over two 8 oz (237 mL) cups of coffee.
The evidence for or against the importance of limiting caffeine
intake during pregnancy is insufficient and of low quality. There are
conflicting reports in the scientific literature about caffeine
consumption during pregnancy. A 2011 risk analysis review found that
caffeine consumption during pregnancy does not appear to increase the
risk of congenital malformations , miscarriage or growth retardation
even when consumed in moderate to high amounts. There is some
evidence that the hormonal changes during pregnancy slow the metabolic
clearance of caffeine from the system, causing a given dose to have
longer-lasting effects (as long as 15 hours in the third trimester).
There is some evidence that higher caffeine intake by pregnant women
may be associated with a higher risk of giving birth to a low birth
weight baby, and may be associated with a higher risk of pregnancy
loss. A systematic review, analyzing the results of observational
studies, suggests that women who consume large amounts of caffeine
(greater than 300 mg/day) prior to becoming pregnant may have a higher
risk of experiencing pregnancy loss.
Caffeine can increase blood pressure and cause vasoconstriction .
Long-term consumption at sufficiently high doses has been associated
with chronic arterial stiffness.
Coffee and caffeine can affect
gastrointestinal motility and gastric acid secretion.
low doses may cause weak bronchodilation for up to four hours in
Caffeine increases basal metabolic rate in adults. In
postmenopausal women, high caffeine consumption can accelerate bone
Doses of caffeine equivalent to the amount normally found in standard
servings of tea, coffee and carbonated soft drinks appear to have no
diuretic action. However, acute ingestion of caffeine in large doses
(at least 250–300 mg, equivalent to the amount found in 2–3 cups
of coffee or 5–8 cups of tea) results in a short-term stimulation of
urine output in individuals who have been deprived of caffeine for a
period of days or weeks. This increase is due to both a diuresis
(increase in water excretion) and a natriuresis (increase in saline
excretion); it is mediated via proximal tubular adenosine receptor
blockade. The acute increase in urinary output may increase the risk
of dehydration . However, chronic users of caffeine develop a
tolerance to this effect, and experience no increase in urinary
Minor undesired symptoms from caffeine ingestion not sufficiently
severe to warrant a psychiatric diagnosis are common, and include mild
anxiety, jitteriness, insomnia, increased sleep latency, and reduced
Caffeine can have negative effects on anxiety
disorders . According to a 2011 literature review, caffeine use is
positively associated with anxiety and panic disorders. At high
doses, typically greater than 300 mg, caffeine can both cause and
worsen anxiety. For some people, discontinuing caffeine use can
significantly reduce anxiety.
In moderate doses, caffeine may reduce symptoms of depression and
lower suicide risk.
Some textbooks state that caffeine is a mild euphoriant, others
state that it is not a euphoriant, and one states that it is and is
not a euphoriant.
Whether or not caffeine can result in an addictive disorder depends
on how addiction is defined. Some diagnostic models, such as the
ICD-10 , include a classification of caffeine addiction
under a broader diagnostic model. Some state that certain users can
become addicted and therefore unable to decrease use even though they
know there are negative health effects.
Caffeine does not appear to be a reinforcing stimulus, and some
degree of aversion may actually occur, with people preferring placebo
over caffeine in a study on drug abuse liability published in an NIDA
research monograph. Some state that research does not provide support
for an underlying biochemical mechanism for caffeine addiction.
Other research states it can affect the reward system.
Caffeine addiction" was added to the ICDM-9 and ICD-10. However, its
addition was contested with claims that this diagnostic model of
caffeine addiction is not supported by evidence. The American
Psychiatric Association 's
DSM-5 does not include the diagnosis of a
caffeine addiction but proposes criteria for the disorder for more
Dependence And Withdrawal
Withdrawal can cause mild to clinically significant distress or
impairment in daily functioning. The frequency at which this occurs is
self reported at 11%, but in lab tests only half of the people who
report withdrawal actually experience it, casting doubt on many claims
of dependence. Mild to increasingly severe physical dependence and
withdrawal symptoms may occur upon abstinence, with greater than 100
mg caffeine per day; some symptoms associated with psychological
dependence may also occur during withdrawal .
Caffeine dependence can
involve withdrawal symptoms such as fatigue, headache, irritability,
depressed mood, reduced contentedness, inability to concentrate,
sleepiness or drowsiness, stomach pain , and joint pain . Withdrawal
headaches are experienced by roughly half of those who stop consuming
caffeine for two days following an average daily intake of 235 mg.
ICD-10 includes a diagnostic model for caffeine dependence , but
DSM-5 does not. The APA , which published the DSM-5,
acknowledged that there was sufficient evidence in order to create a
diagnostic model of caffeine dependence for the DSM-5, but they noted
that the clinical significance of this disorder is unclear. The DSM-5
instead lists "caffeine use disorder" in the emerging models section
of the manual.
Tolerance varies for daily, regular caffeine users and high caffeine
users. High doses of caffeine (750 to 1200 mg/day spread throughout
the day) have been shown to produce complete tolerance to some, but
not all of the effects of caffeine. Doses as low as 100 mg/day, such
as a 6 oz cup of coffee or two to three 12 oz servings of caffeinated
soft-drink, may continue to cause sleep disruption, among other
intolerances. Non-regular caffeine users have the least caffeine
tolerance for sleep disruption. Some coffee drinkers develop
tolerance to its undesired sleep-disrupting effects, but others
apparently do not.
RISK OF OTHER DISEASES
Coffee § Health and pharmacology
A protective effect of caffeine against Alzheimer\'s disease is
possible, but the evidence is inconclusive.
intraocular pressure in those with glaucoma but does not appear to
affect normal individuals. It may protect people from liver cirrhosis
Caffeine may lessen the severity of acute mountain sickness if
taken a few hours prior to attaining a high altitude.
Primary symptoms of caffeine intoxication
Consumption of 1–1.5 grams per day is associated with a condition
known as caffeinism. Caffeinism usually combines caffeine dependency
with a wide range of unpleasant symptoms including nervousness,
irritability, restlessness, insomnia, headaches, and palpitations
after caffeine use.
Caffeine overdose can result in a state of central nervous system
over-stimulation called caffeine intoxication (
DSM-IV 305.90). This
syndrome typically occurs only after ingestion of large amounts of
caffeine, well over the amounts found in typical caffeinated beverages
and caffeine tablets (e.g., more than 400–500 mg at a time). The
symptoms of caffeine intoxication are comparable to the symptoms of
overdoses of other stimulants : they may include restlessness,
fidgeting, anxiety, excitement, insomnia, flushing of the face,
increased urination, gastrointestinal disturbance, muscle twitching, a
rambling flow of thought and speech, irritability, irregular or rapid
heart beat, and psychomotor agitation . In cases of much larger
overdoses, mania , depression , lapses in judgment, disorientation ,
disinhibition , delusions, hallucinations, or psychosis may occur, and
rhabdomyolysis (breakdown of skeletal muscle tissue) can be provoked.
Massive overdose can result in death. The LD50 of caffeine in
humans is dependent on individual sensitivity, but is estimated to be
150 to 200 milligrams per kilogram of body mass (75–100 cups of
coffee for a 70 kilogram adult). A number of fatalities have been
caused by overdoses of readily available powdered caffeine
supplements, for which the estimated lethal amount is less than a
tablespoon. The lethal dose is lower in individuals whose ability to
metabolize caffeine is impaired due to genetics or chronic liver
disease A death was reported in a man with liver cirrhosis who
overdosed on caffeinated mints.
Treatment of mild caffeine intoxication is directed toward symptom
relief; severe intoxication may require peritoneal dialysis ,
hemodialysis , or hemofiltration .
Caffeinated alcoholic energy drink
According to DSST , alcohol provides a reduction in performance and
caffeine has a significant improvement in performance. When alcohol
and caffeine are consumed jointly, the effects produced by caffeine
are affected, but the alcohol effects remain the same. For example,
when additional caffeine is added, the drug effect produced by alcohol
is not reduced. However, the jitteriness and alertness given by
caffeine is decreased when additional alcohol is consumed. Alcohol
consumption alone reduces both inhibitory and activational aspects of
Caffeine antagonizes the activational aspect of
behavioral control, but has no effect on the inhibitory behavioral
Smoking tobacco increases caffeine clearance by 56%.
ORAL BIRTH CONTROL
Consumption of caffeine while orally administering birth control can
extend the half-life of caffeine; therefore, greater attention should
be taken during caffeine consumption.
Caffeine may increase the effectiveness of some medications including
ones used to treat headaches .
STRUCTURE OF A TYPICAL CHEMICAL SYNAPSE
Axon terminal Synaptic cleft
Caffeine's primary mechanism of action is as an antagonist of
adenosine receptors in the brain
In the absence of caffeine and when a person is awake and alert,
little adenosine is present in (CNS) neurons. With a continued wakeful
state, over time it accumulates in the neuronal synapse , in turn
binding to and activating adenosine receptors found on certain CNS
neurons; when activated, these receptors produce a cellular response
that ultimately increases drowsiness . When caffeine is consumed, it
antagonizes adenosine receptors; in other words, caffeine prevents
adenosine from activating the receptor by blocking the location on the
receptor where adenosine binds to it. As a result, caffeine
temporarily prevents or relieves drowsiness, and thus maintains or
Receptor And Ion Channel Targets
Caffeine is a receptor antagonist at all adenosine receptor subtypes
(A1 , A2A , A2B , and A3 receptors). Antagonism at these receptors
stimulates the medullary vagal, vasomotor, and respiratory centers ,
which increases respiratory rate, reduces heartrate, and constricts
Adenosine receptor antagonism also promotes
neurotransmitter release (e.g., monoamines and acetylcholine ), which
endows caffeine with its stimulant effects; adenosine acts as an
inhibitory neurotransmitter that suppresses activity in the central
nervous system. Heart palpitations are caused by blockade of the
adenosine A1 receptor.
Because caffeine is both water- and lipid-soluble, it readily crosses
the blood–brain barrier that separates the bloodstream from the
interior of the brain. Once in the brain, the principal mode of action
is as a nonselective antagonist of adenosine receptors (in other
words, an agent that reduces the effects of adenosine). The caffeine
molecule is structurally similar to adenosine, and is capable of
binding to adenosine receptors on the surface of cells without
activating them, thereby acting as a competitive antagonist .
In addition to its activity at adenosine receptors, caffeine is an
inositol trisphosphate receptor 1 antagonist and a voltage-independent
activator of the ryanodine receptors (
RYR2 , and
RYR3 ). It is
also a competitive antagonist of the ionotropic glycine receptor .
Effects On Striatal Dopamine
While caffeine does not directly bind to any dopamine receptors , it
influences the binding activity of dopamine at its receptors in the
striatum by binding to adenosine receptors that have formed GPCR
heteromers with dopamine receptors, specifically the A1 –D1 receptor
heterodimer (this is a receptor complex with 1 adenosine A1 receptor
and 1 dopamine D1 receptor) and the A2A –D2 receptor heterotetramer
(this is a receptor complex with 2 adenosine A2A receptors and 2
dopamine D2 receptors). The A2A–D2 receptor heterotetramer has
been identified as a primary pharmacological target of caffeine,
primarily because it mediates some of its psychostimulant effects and
its pharmacodynamic interactions with dopaminergic psychostimulants.
Caffeine also causes the release of dopamine in the dorsal striatum
and nucleus accumbens core (a substructure within the ventral striatum
), but not the nucleus accumbens shell , by antagonizing A1 receptors
in the axon terminal of dopamine neurons and A1 –A2A heterodimers (a
receptor complex composed of 1 adenosine A1 receptor and 1 adenosine
A2A receptor) in the axon terminal of glutamate neurons. During
chronic caffeine use, caffeine-induced dopamine release within the
nucleus accumbens core is markedly reduced due to drug tolerance .
Caffeine, like other xanthines , also acts as a phosphodiesterase
inhibitor . As a competitive nonselective phosphodiesterase inhibitor
, caffeine raises intracellular cAMP , activates protein kinase A ,
inhibits TNF-alpha and leukotriene synthesis, and reduces
inflammation and innate immunity .
Caffeine also affects the
cholinergic system where it inhibits the enzyme acetylcholinesterase .
Caffeine antagonizes adenosine A2A receptors in the ventrolateral
preoptic area (VLPO), thereby reducing inhibitory GABA
neurotransmission to the tuberomammillary nucleus , a histaminergic
projection nucleus that activation-dependently promotes arousal.
Disinhibition of the tuberomammillary nucleus is the chief mechanism
by which caffeine produces wakefulness-promoting effects.
Caffeine is metabolized in the liver into three primary
metabolites: paraxanthine (84%), theobromine (12%), and theophylline
(4%) Urinary metabolites of caffeine in humans at 48 hours
Caffeine from coffee or other beverages is absorbed by the small
intestine within 45 minutes of ingestion and distributed throughout
all bodily tissues. Peak blood concentration is reached within 1–2
hours. It is eliminated by first-order kinetics .
Caffeine can also
be absorbed rectally, evidenced by suppositories of ergotamine
tartrate and caffeine (for the relief of migraine ) and chlorobutanol
and caffeine (for the treatment of hyperemesis ). However, rectal
absorption is less efficient than oral: the maximum concentration
(Cmax ) and total amount absorbed (AUC ) are both about 30% (i.e.
1/3.5) of the oral amounts.
Caffeine's biological half-life – the time required for the body to
eliminate one-half of a dose – varies widely among individuals
according to factors such as pregnancy, other drugs, liver enzyme
function level (needed for caffeine metabolism) and age. In healthy
adults, caffeine's half-life is between 3–7 hours. Smoking
decreases the half-life by 30–50%, while oral contraceptives can
double it and pregnancy can raise it to as much as 15 hours during
the last trimester. In newborns the half-life can be 80 hours or
more, dropping very rapidly with age, possibly to less than the adult
value by age 6 months. The antidepressant fluvoxamine (Luvox) reduces
the clearance of caffeine by more than 90%, and increases its
elimination half-life more than tenfold; from 4.9 hours to 56 hours.
Caffeine is metabolized in the liver by the cytochrome P450 oxidase
enzyme system, in particular, by the
CYP1A2 isozyme, into three
dimethylxanthines , each of which has its own effects on the body:
Paraxanthine (84%): Increases lipolysis , leading to elevated
glycerol and free fatty acid levels in blood plasma .
Theobromine (12%): Dilates blood vessels and increases urine
Theobromine is also the principal alkaloid in the cocoa bean
Theophylline (4%): Relaxes smooth muscles of the bronchi , and is
used to treat asthma . The therapeutic dose of theophylline, however,
is many times greater than the levels attained from caffeine
1,3,7-Trimethyluric acid is a minor caffeine metabolite. Each of
these metabolites is further metabolized and then excreted in the
Caffeine can accumulate in individuals with severe liver
disease , increasing its half-life.
A 2011 review found that increased caffeine intake was associated
with a variation in two genes that increase the rate of caffeine
catabolism. Subjects who had this mutation on both chromosomes
consumed 40 mg more caffeine per day than others. This is presumably
due to the need for a higher intake to achieve a comparable desired
effect, not that the gene led to a disposition for greater incentive
Pure anhydrous caffeine is a bitter-tasting white odorless powder
with a melting point of 235–238 °C.
Caffeine is moderately
soluble in water at room temperature (2 g/100 mL), but very soluble in
boiling water (66 g/100 mL). It is also moderately soluble in ethanol
(1.5 g/100 mL). It is weakly basic (pKa of conjugate base = ~0.6)
requiring strong acid to protonate it.
Caffeine does not contain any
stereogenic centers and hence is classified as an achiral molecule.
The xanthine core of caffeine contains two fused rings, a
pyrimidinedione and imidazole . The pyrimidinedione in turn contains
two amide functional groups that exist predominately in a zwitterionic
resonance the location from which the nitrogen atoms are double bonded
to their adjacent amide carbons atoms. Hence all six of the atoms
within the pyrimidinedione ring system are sp2 hybridized and planar.
Therefore, the fused 5,6 ring core of caffeine contains a total of ten
pi electrons and hence according to Hückel\'s rule is aromatic .
One biosynthetic route of caffeine, as performed by
Coffea species. One laboratory synthesis of caffeine
The biosynthesis of caffeine is an example of convergent evolution
among different species.
Caffeine may be synthesized in the lab starting with dimethylurea and
malonic acid .
Commercial supplies of caffeine are not usually manufactured
synthetically because the chemical it is readily available as a
byproduct of decaffeination.
Decaffeination Fibrous crystals of purified
Dark field light microscope image, the image covers an area
of approx. 7 x 11mm.
Extraction of caffeine from coffee, to produce caffeine and
decaffeinated coffee, can be performed using a number of solvents.
Benzene , chloroform , trichloroethylene , and dichloromethane have
all been used over the years but for reasons of safety, environmental
impact, cost, and flavor, they have been superseded by the following
* WATER EXTRACTION:
Coffee beans are soaked in water. The water,
which contains many other compounds in addition to caffeine and
contributes to the flavor of coffee, is then passed through activated
charcoal , which removes the caffeine. The water can then be put back
with the beans and evaporated dry, leaving decaffeinated coffee with
its original flavor.
Coffee manufacturers recover the caffeine and
resell it for use in soft drinks and over-the-counter caffeine
* SUPERCRITICAL CARBON DIOXIDE EXTRACTION: Supercritical carbon
dioxide is an excellent nonpolar solvent for caffeine, and is safer
than the organic solvents that are otherwise used. The extraction
process is simple: CO2 is forced through the green coffee beans at
temperatures above 31.1 °C and pressures above 73 atm . Under these
conditions, CO2 is in a "supercritical " state : It has gaslike
properties that allow it to penetrate deep into the beans but also
liquid-like properties that dissolve 97–99% of the caffeine. The
caffeine-laden CO2 is then sprayed with high pressure water to remove
the caffeine. The caffeine can then be isolated by charcoal adsorption
(as above) or by distillation , recrystallization , or reverse osmosis
* EXTRACTION BY ORGANIC SOLVENTS: Certain organic solvents such as
ethyl acetate present much less health and environmental hazard than
chlorinated and aromatic organic solvents used formerly. Another
method is to use triglyceride oils obtained from spent coffee grounds.
"Decaffeinated" coffees do in fact contain caffeine in many cases –
some commercially available decaffeinated coffee products contain
considerable levels. One study found that decaffeinated coffee
contained 10 mg of caffeine per cup, compared to approximately 85 mg
of caffeine per cup for regular coffee.
DETECTION IN BODY FLUIDS
Caffeine can be quantified in blood, plasma, or serum to monitor
therapy in neonates, confirm a diagnosis of poisoning, or facilitate a
medicolegal death investigation. Plasma caffeine levels are usually in
the range of 2–10 mg/L in coffee drinkers, 12–36 mg/L in neonates
receiving treatment for apnea, and 40–400 mg/L in victims of acute
overdosage. Urinary caffeine concentration is frequently measured in
competitive sports programs, for which a level in excess of 15 mg/L is
usually considered to represent abuse.
Some analog substances have been created which mimic caffeine's
properties with either function or structure or both. Of the latter
group are the xanthines
DMPX and 8-chlorotheophylline , which is an
ingredient in dramamine . Members of a class of nitrogen substituted
xanthines are often proposed as potential alternatives to caffeine.
Many other xanthine analogues constituting the adenosine receptor
antagonist class have also been elucidated.
Some other caffeine analogs:
Roasted coffee beans
Around sixty plant species are known to contain caffeine. Common
sources are the "beans" (seeds) of the two cultivated coffee plants,
Coffea arabica and C. canephora (the quantity varies, but 1.3% is a
typical value ); in the leaves of the tea bush ; and in kola nuts .
Other sources include yaupon holly leaves, South American holly yerba
mate leaves, seeds from Amazonian maple guarana berries, and Amazonian
holly guayusa leaves. Temperate climates around the world have
produced unrelated caffeine containing plants.
Caffeine in plants acts as a natural pesticide : it can paralyze and
kill predator insects feeding on the plant. High caffeine levels are
found in coffee seedlings when they are developing foliage and lack
mechanical protection. In addition, high caffeine levels are found in
the surrounding soil of coffee seedlings, which inhibits seed
germination of nearby coffee seedlings, thus giving seedlings with the
highest caffeine levels fewer competitors for existing resources for
Caffeine is stored in tea leaves in two places. Firstly, in
the cell vacuoles where it is complexed with polyphenols . This
caffeine probably is released into the mouth parts of insects, to
discourage herbivory. Secondly, around the vascular bundles, where it
probably inhibits pathogenic fungi from entering and colonizing the
Caffeine in nectar may improve the reproductive
success of the pollen producing plants by enhancing the reward memory
of pollinators such as honeybees .
The differing perceptions in the effects of ingesting beverages made
from various plants containing caffeine could be explained by the fact
that these beverages also contain varying mixtures of other
methylxanthine alkaloids , including the cardiac stimulants
theophylline and theobromine , and polyphenols that can form insoluble
complexes with caffeine.
Caffeine content in select food and drugs
CAFFEINE PER SERVING (MG )
CAFFEINE (MG/L )
Caffeine tablet (regular-strength)
Caffeine tablet (extra-strength)
Special Dark (45% cacao content)
1 bar (43 g or 1.5 oz)
Chocolate (11% cacao content)
1 bar (43 g or 1.5 oz)
207 mL (7.0 US fl oz )
207 mL (7.0 US fl oz)
207 mL (7.0 US fl oz)
44–60 mL (1.5–2.0 US fl oz)
Tea – black, green, and other types , – steeped for 3 min.
177 millilitres (6.0 US fl oz)
Guayakí yerba mate (loose leaf)
6 g (0.21 oz)
355 mL (12.0 US fl oz)
355 mL (12.0 US fl oz)
355 mL (12.0 US fl oz)
350 mL (12 US fl oz)
695 mL (23.5 US fl oz)
250 mL (8.5 US fl oz)
Products containing caffeine are coffee, tea, soft drinks ("colas"),
energy drinks , other beverages, chocolate , caffeine tablets, other
oral products, and inhalation.
The world's primary source of caffeine is the coffee "bean" (the seed
of the coffee plant ), from which coffee is brewed.
in coffee varies widely depending on the type of coffee bean and the
method of preparation used; even beans within a given bush can show
variations in concentration. In general, one serving of coffee ranges
from 80 to 100 milligrams, for a single shot (30 milliliters) of
arabica-variety espresso , to approximately 100–125 milligrams for a
cup (120 milliliters) of drip coffee . Arabica coffee typically
contains half the caffeine of the robusta variety. In general,
dark-roast coffee has very slightly less caffeine than lighter roasts
because the roasting process reduces caffeine content of the bean by a
Tea contains more caffeine than coffee by dry weight. A typical
serving, however, contains much less, since tea is normally brewed
more weakly than coffee. Also contributing to caffeine content are
growing conditions, processing techniques, and other variables. Thus,
teas contain varying amounts of caffeine.
Tea contains small amounts of theobromine and slightly higher levels
of theophylline than coffee. Preparation and many other factors have a
significant impact on tea, and color is a very poor indicator of
caffeine content. Teas like the pale Japanese green tea , gyokuro ,
for example, contain far more caffeine than much darker teas like
lapsang souchong , which has very little.
Soft Drinks And Energy Drinks
Caffeine is also a common ingredient of soft drinks , such as cola ,
originally prepared from kola nuts . Soft drinks typically contain 0
to 55 milligrams of caffeine per 12 ounce serving. By contrast,
energy drinks , such as
Red Bull , can start at 80 milligrams of
caffeine per serving. The caffeine in these drinks either originates
from the ingredients used or is an additive derived from the product
of decaffeination or from chemical synthesis. Guarana, a prime
ingredient of energy drinks, contains large amounts of caffeine with
small amounts of theobromine and theophylline in a naturally occurring
slow-release excipient .
* Mate is a drink popular in many parts of South America. Its
preparation consists of filling a gourd with the leaves of the South
American holly yerba mate , pouring hot but not boiling water over the
leaves, and drinking with a straw, the bombilla, which acts as a
filter so as to draw only the liquid and not the yerba leaves.
Guaraná seeds ("beans") are used in making the commercially sold
Guaraná Antarctica , which originated in Brazil and is
currently the fifteenth most popular soft drink in the world.
* The leaves of
Ilex guayusa , the Ecuadorian holly tree, are placed
in boiling water to make a guayusa tea, which is both brewed locally
and sold commercially throughout the world.
Chocolate derived from cocoa beans contains a small amount of
caffeine. The weak stimulant effect of chocolate may be due to a
combination of theobromine and theophylline, as well as caffeine. A
typical 28-gram serving of a milk chocolate bar has about as much
caffeine as a cup of decaffeinated coffee. By weight, dark chocolate
has one to two times the amount of caffeine as coffee: 80–160 mg per
No-Doz 100 mg caffeine tablets
Tablets offer the advantages over coffee and tea of convenience,
known dosage, and avoiding concomitant sugar, acid and fluid intake.
Manufacturers of caffeine tablets claim that using caffeine of
pharmaceutical quality improves mental alertness. These tablets are
commonly used by students studying for their exams and by people who
work or drive for long hours.
OTHER ORAL PRODUCTS
One U.S. company is marketing oral dissolvable caffeine strips.
Another intake route is
SpazzStick , a caffeinated lip balm . Alert
Caffeine Gum was introduced in the United States in 2013, but
was voluntarily withdrawn after an announcement of an investigation by
the FDA of the health effects of added caffeine in foods.
There are several products being marketed that offer inhalers that
deliver proprietary blends of supplements, with caffeine being a key
ingredient. In 2012, the FDA sent a warning letter to one of the
companies marketing these inhalers, expressing concerns for the lack
of safety information available about inhaled caffeine.
COMBINATIONS WITH OTHER DRUGS
* Some beverages combine alcohol with caffeine to create a
caffeinated alcoholic drink . The stimulant effects of caffeine may
mask the depressant effects of alcohol, potentially reducing the
user's awareness of their level of intoxication . Such beverages have
been the subject of bans due to safety concerns. In particular, United
Food and Drug Administration
Food and Drug Administration has classified caffeine added to
malt liquor beverages as an "unsafe food additive".
Ya ba contains a combination of methamphetamine and caffeine.
DISCOVERY AND SPREAD OF USE
Coffeehouse in Palestine , circa 1900 Main articles: History
of chocolate ,
History of coffee ,
History of tea , and History of
According to Chinese legend, the Chinese emperor
Shennong , reputed
to have reigned in about 3000 BCE, accidentally discovered tea when he
noted that when certain leaves fell into boiling water, a fragrant and
restorative drink resulted.
Shennong is also mentioned in Lu Yu's Cha
Jing , a famous early work on the subject of tea.
The earliest credible evidence of either coffee drinking or knowledge
of the coffee tree appears in the middle of the fifteenth century, in
Sufi monasteries of the Yemenin southern Arabia. From Mocha ,
coffee spread to Egypt and North Africa, and by the 16th century, it
had reached the rest of the Middle East, Persia and Turkey . From the
Middle East, coffee drinking spread to Italy, then to the rest of
Europe, and coffee plants were transported by the Dutch to the East
Indies and to the Americas.
Kola nut use appears to have ancient origins. It is chewed in many
West African cultures, individually or in a social setting, to restore
vitality and ease hunger pangs.
The earliest evidence of cocoa bean use comes from residue found in
an ancient Mayan pot dated to 600 BCE. Also, chocolate was consumed in
a bitter and spicy drink called xocolatl, often seasoned with vanilla
, chile pepper , and achiote . Xocolatl was believed to fight fatigue,
a belief probably attributable to the theobromine and caffeine
Chocolate was an important luxury good throughout
Mesoamerica , and cocoa beans were often used as
Xocolatl was introduced to
Europe by the Spaniards , and became a
popular beverage by 1700. The Spaniards also introduced the cacao tree
West Indies and the
Philippines . It was used in alchemical
processes, where it was known as "black bean".
The leaves and stems of the yaupon holly (
Ilex vomitoria ) were used
by Native Americans to brew a tea called asi or the "black drink ".
Archaeologists have found evidence of this use far into antiquity,
possibly dating to Late Archaic times .
CHEMICAL IDENTIFICATION, ISOLATION, AND SYNTHESIS
Pierre Joseph Pelletier
Pierre Joseph Pelletier
In 1819, the German chemist
Friedlieb Ferdinand Runge isolated
relatively pure caffeine for the first time; he called it "Kaffebase"
(i.e. a base that exists in coffee). According to Runge, he did this
at the behest of
Johann Wolfgang von Goethe
Johann Wolfgang von Goethe . In 1821, caffeine was
isolated both by the French chemist
Pierre Jean Robiquet and by
another pair of French chemists, Pierre-Joseph Pelletier and Joseph
Bienaimé Caventou , according to Swedish chemist Jöns Jacob
Berzelius in his yearly journal. Furthermore, Berzelius stated that
the French chemists had made their discoveries independently of any
knowledge of Runge's or each other's work. However, Berzelius later
acknowledged Runge's priority in the extraction of caffeine, stating:
"However, at this point, it should not remain unmentioned that Runge
(in his Phytochemical Discoveries, 1820, pages 146–147) specified
the same method and described caffeine under the name Caffeebase a
year earlier than Robiquet, to whom the discovery of this substance is
usually attributed, having made the first oral announcement about it
at a meeting of the Pharmacy Society in Paris."
Pelletier's article on caffeine was the first to use the term in
print (in the French form Caféine from the French word for coffee:
café). It corroborates Berzelius's account:
Caffeine, noun (feminine). Crystallizable substance discovered in
coffee in 1821 by Mr. Robiquet. During the same period – while they
were searching for quinine in coffee because coffee is considered by
several doctors to be a medicine that reduces fevers and because
coffee belongs to the same family as the cinchona tree – on their
part, Messrs. Pelletier and Caventou obtained caffeine; but because
their research had a different goal and because their research had not
been finished, they left priority on this subject to Mr. Robiquet. We
do not know why Mr.
Robiquet has not published the analysis of coffee
which he read to the Pharmacy Society. Its publication would have
allowed us to make caffeine better known and give us accurate ideas of
coffee's composition ...
Robiquet was one of the first to isolate and describe the properties
of pure caffeine, whereas Pelletier was the first to perform an
elemental analysis .
In 1827, M. Oudry isolated "théine" from tea, but it was later
proved by Mulder and by Carl Jobst that theine was actually
In 1895, German chemist
Hermann Emil Fischer (1852–1919) first
synthesized caffeine from its chemical components (i.e. a "total
synthesis "), and two years later, he also derived the structural
formula of the compound. This was part of the work for which Fischer
was awarded the Nobel Prize in 1902.
Because it was recognized that coffee contained some compound that
acted as a stimulant, first coffee and later also caffeine has
sometimes been subject to regulation. For example, in the 16th century
Mecca and in the
Ottoman Empire made coffee illegal for
Charles II of England
Charles II of England tried to ban it in 1676,
Frederick II of Prussia banned it in 1777, and coffee was banned in
Sweden at various times between 1756 and 1823.
In 1911, caffeine became the focus of one of the earliest documented
health scares, when the US government seized 40 barrels and 20 kegs of
Cola syrup in
Chattanooga, Tennessee , alleging the caffeine in
its drink was "injurious to health". Although the judge ruled in
favor of Coca-Cola, two bills were introduced to the U.S. House of
Representatives in 1912 to amend the
Pure Food and Drug Act , adding
caffeine to the list of "habit-forming" and "deleterious" substances,
which must be listed on a product's label.
SOCIETY AND CULTURE
Food and Drug Administration
Food and Drug Administration (FDA) in the United States currently
allows only beverages containing less than 0.02% caffeine; but
caffeine powder, which is sold as a dietary supplement, is
unregulated. It is a regulatory requirement that the label of most
prepackaged foods must declare a list of ingredients, including food
additives such as caffeine, in descending order of proportion.
However, there is no regulatory provision for mandatory quantitative
labeling of caffeine, (e.g., milligrams caffeine per stated serving
size). There are a number of food ingredients that naturally contain
caffeine. These ingredients must appear in food ingredient lists.
However, as is the case for "food additive caffeine", there is no
requirement to identify the quantitative amount of caffeine in
composite foods containing ingredients that are natural sources of
caffeine. While coffee or chocolate are broadly recognized as caffeine
sources, some ingredients (e.g. guarana , yerba maté ) are likely
less recognized as caffeine sources. For these natural sources of
caffeine, there is no regulatory provision requiring that a food label
identify the presence of caffeine nor state the amount of caffeine
present in the food.
Global consumption of caffeine has been estimated at 120,000 tonnes
per year, making it the world's most popular psychoactive substance.
This amounts to one serving of a caffeinated beverage for every person
Some Seventh-day Adventists ,
Church of God (Restoration) adherents,
Christian Scientists do not consume caffeine. Some from these
religions believe that one is not supposed to consume a non-medical,
psychoactive substance, or believe that one is not supposed to consume
a substance that is addictive. The Church of Jesus Christ of
Latter-day Saints has said the following with regard to caffeinated
beverages: " . . . the Church revelation spelling out health practices
(Doctrine and Covenants 89) does not mention the use of caffeine. The
Church's health guidelines prohibit alcoholic drinks, smoking or
chewing of tobacco, and 'hot drinks' – taught by Church leaders to
refer specifically to tea and coffee."
Gaudiya Vaishnavas generally also abstain from caffeine, because they
believe it clouds the mind and over-stimulates the senses. To be
initiated under a guru, one must have had no caffeine, alcohol,
nicotine or other drugs, for at least a year.
Caffeinated beverages are widely consumed by
Muslims today. In the
16th century, some Muslim authorities made unsuccessful attempts to
ban them as forbidden "intoxicating beverages" under Islamic dietary
Caffeine effects on spider webs See also: Effect of
psychoactive drugs on animals
Recently discovered bacteria
Pseudomonas putida CBB5 can live on pure
caffeine, and can cleave caffeine into carbon dioxide and ammonia.
Caffeine is toxic to birds and to dogs and cats, and has a
pronounced adverse effect on mollusks , various insects, and spiders .
This is at least partly due to a poor ability to metabolize the
compound, causing higher levels for a given dose per unit weight.
Caffeine has also been found to enhance the reward memory of honeybees
Caffeine has been used to double chromosomes in haploid wheat .
* ^ A B C D E F G Malenka RC, Nestler EJ, Hyman SE (2009). "Chapter
15: Reinforcement and Addictive Disorders". In Sydor A, Brown RY.
Molecular Neuropharmacology: A Foundation for Clinical Neuroscience
(2nd ed.). New York: McGraw-Hill Medical. p. 375. ISBN
978-0-07-148127-4 . Long-term caffeine use can lead to mild physical
dependence. A withdrawal syndrome characterized by drowsiness,
irritability, and headache typically lasts no longer than a day. True
compulsive use of caffeine has not been documented.
* ^ A B C Karch SB (2009). Karch\'s pathology of drug abuse (4th
ed.). Boca Raton: CRC Press. pp. 229–230. ISBN 978-0-8493-7881-2 .
The suggestion has also been made that a caffeine dependence syndrome
exists ... In one controlled study, dependence was diagnosed in 16 of
99 individuals who were evaluated. The median daily caffeine
consumption of this group was only 357 mg per day (Strain et al.,
Since this observation was first published, caffeine addiction has
been added as an official diagnosis in ICDM 9. This decision is
disputed by many and is not supported by any convincing body of
experimental evidence. ... All of these observations strongly suggest
that caffeine does not act on the dopaminergic structures related to
addiction, nor does it improve performance by alleviating any symptoms
of withdrawal * ^ A B C D E F American Psychiatric Association
(2013). "Substance-Related and Addictive Disorders" (PDF). American
Psychiatric Publishing. pp. 1–2. Archived from the original (PDF) on
15 August 2015. Retrieved 10 July 2015. Substance use disorder in
DSM-5 combines the
DSM-IV categories of substance abuse and substance
dependence into a single disorder measured on a continuum from mild to
severe. ... Additionally, the diagnosis of dependence caused much
confusion. Most people link dependence with "addiction" when in fact
dependence can be a normal body response to a substance. ... DSM-5
will not include caffeine use disorder, although research shows that
as little as two to three cups of coffee can trigger a withdrawal
effect marked by tiredness or sleepiness. There is sufficient evidence
to support this as a condition, however it is not yet clear to what
extent it is a clinically significant disorder.
* ^ A B Introduction to Pharmacology (third ed.). Abingdon: CRC
Press. 2007. pp. 222–223. ISBN 978-1-4200-4742-4 .
* ^ A B C D Juliano LM, Griffiths RR (October 2004). "A critical
review of caffeine withdrawal: empirical validation of symptoms and
signs, incidence, severity, and associated features" (PDF).
Psychopharmacology. 176 (1): 1–29. PMID 15448977 . doi
:10.1007/s00213-004-2000-x . Archived (PDF) from the original on 29
January 2012. Results: Of 49 symptom categories identified, the
following 10 fulfilled validity criteria: headache, fatigue, decreased
energy/ activeness, decreased alertness, drowsiness, decreased
contentedness, depressed mood, difficulty concentrating, irritability,
and foggy/not clearheaded. In addition, flu-like symptoms,
nausea/vomiting, and muscle pain/stiffness were judged likely to
represent valid symptom categories. In experimental studies, the
incidence of headache was 50% and the incidence of clinically
significant distress or functional impairment was 13%. Typically,
onset of symptoms occurred 12–24 h after abstinence, with peak
intensity at 20–51 h, and for a duration of 2–9 days.
* ^ A B C D E F G H I J K L M N O "Caffeine". DrugBank. University
of Alberta. 16 September 2013. Retrieved 8 August 2014.
* ^ A B C D Poleszak E, Szopa A, Wyska E, Kukuła-Koch W, Serefko
A, Wośko S, Bogatko K, Wróbel A, Wlaź P (February 2016). "Caffeine
augments the antidepressant-like activity of mianserin and agomelatine
in forced swim and tail suspension tests in mice". Pharmacological
Reports. 68 (1): 56–61. PMID 26721352 . doi
* ^ A B "Caffeine". Pubchem Compound. NCBI. Retrieved 16 October
178 °C (sublimes)
238 DEG C (ANHYD)
* ^ A B "Caffeine". ChemSpider. Royal Society of Chemistry.
Retrieved 16 October 2014. Experimental Melting Point:
234–236 °C Alfa Aesar
237 °C Oxford University Chemical Safety Data
238 °C LKT Labs
237 °C Jean-Claude Bradley Open Melting Point Dataset 14937
238 °C Jean-Claude Bradley Open Melting Point Dataset 17008, 17229,
22105, 27892, 27893, 27894, 27895
235.25 °C Jean-Claude Bradley Open Melting Point Dataset 27892,
27893, 27894, 27895
236 °C Jean-Claude Bradley Open Melting Point Dataset 27892, 27893,
235 °C Jean-Claude Bradley Open Melting Point Dataset 6603
234–236 °C Alfa Aesar A10431, 39214
Experimental Boiling Point:
178 °C (Sublimes) Alfa Aesar
178 °C (Sublimes) Alfa Aesar 39214 * ^ A B Nehlig A, Daval JL,
Debry G (1992). "
Caffeine and the central nervous system: mechanisms
of action, biochemical, metabolic and psychostimulant effects". Brain
Research. Brain Research Reviews. 17 (2): 139–70. PMID 1356551 . doi
* ^ Lovett R (24 September 2005). "Coffee: The demon drink?". New
Scientist (2518). (Subscription required (help)).
WHO Model List of Essential Medicines (PDF) (18th ed.). World
Health Organization . October 2013 . p. 34 . Retrieved 23 December
* ^ Cano-Marquina A, Tarín JJ, Cano A (May 2013). "The impact of
coffee on health". Maturitas. 75 (1): 7–21. PMID 23465359 . doi
* ^ Qi H, Li S (April 2014). "Dose-response meta-analysis on
coffee, tea and caffeine consumption with risk of Parkinson's
disease". Geriatrics & Gerontology International. 14 (2): 430–9.
PMID 23879665 . doi :10.1111/ggi.12123 .
Mayo Clinic staff. "Pregnancy Nutrition: Foods to avoid during
pregnancy". Mayo Clinic. Retrieved 15 April 2012.
* ^ A B American College of Obstetricians and Gynecologists (August
2010). "ACOG CommitteeOpinion No. 462: Moderate caffeine consumption
during pregnancy". Obstetrics and Gynecology. 116 (2 Pt 1): 467–8.
PMID 20664420 . doi :10.1097/AOG.0b013e3181eeb2a1 .
* ^ Robertson D, Wade D, Workman R, Woosley RL, Oates JA (April
1981). "Tolerance to the humoral and hemodynamic effects of caffeine
in man" . The Journal of Clinical Investigation. 67 (4): 1111–7. PMC
370671 . PMID 7009653 . doi :10.1172/JCI110124 .
* ^ Kugelman A, Durand M (December 2011). "A comprehensive approach
to the prevention of bronchopulmonary dysplasia". Pediatric
Pulmonology. 46 (12): 1153–65. PMID 21815280 . doi
* ^ Schmidt B (2005). "
Methylxanthine therapy for apnea of
prematurity: evaluation of treatment benefits and risks at age 5 years
in the international
Caffeine for Apnea of Prematurity (CAP) trial".
Biology of the Neonate. 88 (3): 208–13. PMID 16210843 . doi
* ^ Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ,
Ohlsson A, Solimano A, Tin W (May 2006). "
Caffeine therapy for apnea
of prematurity". The New England Journal of Medicine. 354 (20):
2112–21. PMID 16707748 . doi :10.1056/NEJMoa054065 .
* ^ Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ,
Ohlsson A, Solimano A, Tin W (November 2007). "Long-term effects of
caffeine therapy for apnea of prematurity". The New England Journal of
Medicine. 357 (19): 1893–902. PMID 17989382 . doi
* ^ Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos
EV, Davis PG, Tin W, Moddemann D, Solimano A, Ohlsson A, Barrington
KJ, Roberts RS (January 2012). "Survival without disability to age 5
years after neonatal caffeine therapy for apnea of prematurity". JAMA.
307 (3): 275–82. PMID 22253394 . doi :10.1001/jama.2011.2024 .
* ^ Funk GD (November 2009). "Losing sleep over the caffeination of
prematurity" . The Journal of Physiology. 587 (Pt 22): 5299–300. PMC
2793860 . PMID 19915211 . doi :10.1113/jphysiol.2009.182303 .
* ^ Mathew OP (May 2011). "Apnea of prematurity: pathogenesis and
management strategies". Journal of Perinatology. 31 (5): 302–10.
PMID 21127467 . doi :10.1038/jp.2010.126 .
* ^ Henderson-Smart DJ, De Paoli AG (December 2010). "Prophylactic
methylxanthine for prevention of apnoea in preterm infants". The
Cochrane Database of Systematic Reviews (12): CD000432. PMID 21154344
. doi :10.1002/14651858.CD000432.pub2 .
* ^ A B "Caffeine: Summary of Clinical Use". IUPHAR Guide to
Pharmacology. The International Union of Basic and Clinical
Pharmacology. Retrieved 13 February 2015.
* ^ Gupta V, Lipsitz LA (October 2007). "
Orthostatic hypotension in
the elderly: diagnosis and treatment". The American Journal of
Medicine. 120 (10): 841–7. PMID 17904451 . doi
* ^ A B C Bolton S (1981). "Caffeine: Psychological Effects, Use
and Abuse" (PDF). Orthomolecular Psychiatry. 10 (3): 202–211.
* ^ Nehlig A (2010). "Is caffeine a cognitive enhancer?". Journal
of Alzheimer's Disease. 20 Suppl 1: S85–94. PMID 20182035 . doi
Caffeine does not usually affect
performance in learning and memory tasks, although caffeine may
occasionally have facilitatory or inhibitory effects on memory and
Caffeine facilitates learning in tasks in which information
is presented passively; in tasks in which material is learned
intentionally, caffeine has no effect.
performance in tasks involving working memory to a limited extent, but
hinders performance in tasks that heavily depend on this, and caffeine
appears to improve memory performance under suboptimal alertness. Most
studies, however, found improvements in reaction time. The ingestion
of caffeine does not seem to affect long-term memory. ... Its indirect
action on arousal, mood and concentration contributes in large part to
its cognitive enhancing properties.
* ^ Snel J, Lorist MM (2011). "Effects of caffeine on sleep and
cognition". Progress in Brain Research. Progress in Brain Research.
190: 105–17. ISBN 978-0-444-53817-8 . PMID 21531247 . doi
* ^ Ker K, Edwards PJ, Felix LM, Blackhall K, Roberts I (May 2010).
Ker K, ed. "
Caffeine for the prevention of injuries and errors in
shift workers" . The Cochrane Database of Systematic Reviews (5):
CD008508. PMC 4160007 . PMID 20464765 . doi
* ^ A B Camfield DA, Stough C, Farrimond J, Scholey AB (August
2014). "Acute effects of tea constituents L-theanine, caffeine, and
epigallocatechin gallate on cognitive function and mood: a systematic
review and meta-analysis". Nutrition Reviews. 72 (8): 507–22. PMID
24946991 . doi :10.1111/nure.12120 .
* ^ A B C D E F Pesta DH, Angadi SS, Burtscher M, Roberts CK
(December 2013). "The effects of caffeine, nicotine, ethanol, and
tetrahydrocannabinol on exercise performance" . Nutrition &
Metabolism. 10 (1): 71. PMC 3878772 . PMID 24330705 . doi
:10.1186/1743-7075-10-71 . Caffeine-induced increases in performance
have been observed in aerobic as well as anaerobic sports (for
reviews, see ). Trained athletes seem to benefit from a moderate dose
of 5 mg/kg , however, even lower doses of caffeine (1.0–2.0 mg/kg)
may improve performance . Some groups found significantly improved
time trial performance or maximal cycling power , most likely related
to a greater reliance on fat metabolism and decreased neuromuscular
fatigue, respectively. Theophylline, a metabolite of caffeine, seems
to be even more effective in doing so . The effect of caffeine on fat
oxidation, however, may only be significant during lower exercise
intensities and may be blocked at higher intensities . ... For both
caffeine-naïve as well as caffeine-habituated subjects, moderate to
high doses of caffeine are ergogenic during prolonged moderate
intensity exercise . ... In summary, caffeine, even at physiological
doses (3–6 mg/kg), as well as coffee are proven ergogenic aids and
as such – in most exercise situations, especially in endurance-type
events – clearly work-enhancing . It most likely has a peripheral
effect targeting skeletal muscle metabolism as well as a central
effect targeting the brain to enhance performance, especially during
endurance events (see Table 1). Also for anaerobic tasks, the effect
of caffeine on the CNS might be most relevant. ... Muendel et al.
found a 17% improvement in time to exhaustion after nicotine patch
application compared to a placebo without affecting cardiovascular and
respiratory parameters or substrate metabolism. In this sense,
nicotine seems to exert similar effects as caffeine by delaying the
development of central fatigue as impaired central drive is an
important factor contributing to fatigue during exercise. ... The
physiological effects of the above mentioned substances are well
established. However, the ergogenic effect of some of the discussed
drugs may be questioned and one has to consider the cohort tested for
every specific substance. However, only caffeine has enough strength
of evidence to be considered an ergogenic aid.
* ^ Bishop D (December 2010). "Dietary supplements and team-sport
performance". Sports Medicine. 40 (12): 995–1017. PMID 21058748 .
doi :10.2165/11536870-000000000-00000 .
* ^ Conger SA, Warren GL, Hardy MA, Millard-Stafford ML (February
2011). "Does caffeine added to carbohydrate provide additional
ergogenic benefit for endurance?". International Journal of Sport
Nutrition and Exercise Metabolism. 21 (1): 71–84. PMID 21411838 .
doi :10.1123/ijsnem.21.1.71 .
* ^ Liddle DG, Connor DJ (June 2013). "Nutritional supplements and
ergogenic AIDS". Primary Care. 40 (2): 487–505. PMID 23668655 . doi
:10.1016/j.pop.2013.02.009 . Amphetamines and caffeine are stimulants
that increase alertness, improve focus, decrease reaction time, and
delay fatigue, allowing for an increased intensity and duration of
Physiologic and performance effects
• Amphetamines increase dopamine/norepinephrine release and inhibit
their reuptake, leading to central nervous system (CNS) stimulation
• Amphetamines seem to enhance athletic performance in anaerobic
conditions 39 40
• Improved reaction time
• Increased muscle strength and delayed muscle fatigue
• Increased acceleration
• Increased alertness and attention to task * ^ A B C D "It\'s
Your Health – Caffeine".
Health Canada . March 2010. Retrieved 8
* ^ Castellanos FX, Rapoport JL (2002). "Effects of caffeine on
development and behavior in infancy and childhood: A review of the
published literature". Food and Chemical Toxicology. 40 (9):
1235–1242. doi :10.1016/S0278-6915(02)00097-2 .
* ^ Levounis P, Herron AJ (2014). The
Addiction Casebook. American
Psychiatric Pub. p. 49. ISBN 978-1-58562-458-4 .
* ^ "
Food Standards Agency publishes new caffeine advice for
pregnant women". Retrieved 3 August 2009.
* ^ Jahanfar, S; Jaafar, SH (9 June 2015). "Effects of restricted
caffeine intake by mother on fetal, neonatal and pregnancy outcomes.".
The Cochrane database of systematic reviews (6): CD006965. PMID
* ^ Kuczkowski KM (November 2009). "
Caffeine in pregnancy".
Archives of Gynecology and Obstetrics. 280 (5): 695–8. PMID 19238414
. doi :10.1007/s00404-009-0991-6 .
* ^ Brent RL, Christian MS, Diener RM (April 2011). "Evaluation of
the reproductive and developmental risks of caffeine" . Birth Defects
Research. Part B, Developmental and Reproductive Toxicology. 92 (2):
152–87. PMC 3121964 . PMID 21370398 . doi :10.1002/bdrb.20288 .
* ^ A B C D E F Fredholm BB, Bättig K, Holmén J, Nehlig A,
Zvartau EE (March 1999). "Actions of caffeine in the brain with
special reference to factors that contribute to its widespread use".
Pharmacological Reviews. 51 (1): 83–133. PMID 10049999 .
* ^ Chen LW, Wu Y, Neelakantan N, Chong MF, Pan A, van Dam RM
(September 2014). "Maternal caffeine intake during pregnancy is
associated with risk of low birth weight: a systematic review and
dose-response meta-analysis" . BMC Medicine. 12 (1): 174. PMC 4198801
. PMID 25238871 . doi :10.1186/s12916-014-0174-6 .
* ^ Chen LW, Wu Y, Neelakantan N, Chong MF, Pan A, van Dam RM (May
2016). "Maternal caffeine intake during pregnancy and risk of
pregnancy loss: a categorical and dose-response meta-analysis of
prospective studies". Public Health Nutrition. 19 (7): 1233–44. PMID
26329421 . doi :10.1017/S1368980015002463 .
* ^ Lassi ZS, Imam AM, Dean SV, Bhutta ZA (September 2014).
"Preconception care: caffeine, smoking, alcohol, drugs and other
environmental chemical/radiation exposure" . Reproductive Health. 11
Suppl 3: S6. PMC 4196566 . PMID 25415846 . doi
* ^ Daniels JW, Molé PA, Shaffrath JD, Stebbins CL (July 1998).
"Effects of caffeine on blood pressure, heart rate, and forearm blood
flow during dynamic leg exercise". Journal of Applied Physiology. 85
(1): 154–9. PMID 9655769 .
* ^ Bracco D, Ferrarra JM, Arnaud MJ, Jéquier E, Schutz Y (October
1995). "Effects of caffeine on energy metabolism, heart rate, and
methylxanthine metabolism in lean and obese women". The American
Journal of Physiology. 269 (4 Pt 1): E671–8. PMID 7485480 .
* ^ A B Mahmud A, Feely J (August 2001). "Acute effect of caffeine
on arterial stiffness and aortic pressure waveform". Hypertension. 38
(2): 227–31. PMID 11509481 . doi :10.1161/01.HYP.38.2.227 .
* ^ Boekema PJ, Samsom M, van Berge Henegouwen GP, Smout AJ (1999).
Coffee and gastrointestinal function: facts and fiction. A review".
Scandinavian Journal of Gastroenterology. Supplement. 230 (230):
35–9. PMID 10499460 .
* ^ Cohen S, Booth GH (October 1975). "
Gastric acid secretion and
lower-esophageal-sphincter pressure in response to coffee and
caffeine". The New England Journal of Medicine. 293 (18): 897–9.
PMID 1177987 . doi :10.1056/NEJM197510302931803 .
* ^ Sherwood L, Kell R (2009). Human Physiology: From Cells to
Systems (1st Canadian ed.). Nelsen. pp. 613–9. ISBN
* ^ A B Welsh EJ, Bara A, Barley E, Cates CJ (January 2010). Welsh
EJ, ed. "
Caffeine for asthma". The Cochrane Database of Systematic
Reviews (1): CD001112. PMID 20091514 . doi
* ^ Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K,
Jéquier E (May 1980). "
Caffeine and coffee: their influence on
metabolic rate and substrate utilization in normal weight and obese
individuals". The American Journal of Clinical Nutrition. 33 (5):
989–97. PMID 7369170 .
* ^ Dulloo AG, Geissler CA, Horton T, Collins A, Miller DS (January
1989). "Normal caffeine consumption: influence on thermogenesis and
daily energy expenditure in lean and postobese human volunteers". The
American Journal of Clinical Nutrition. 49 (1): 44–50. PMID 2912010
* ^ Koot P, Deurenberg P (1995). "Comparison of changes in energy
expenditure and body temperatures after caffeine consumption". Annals
of Nutrition & Metabolism. 39 (3): 135–42. PMID 7486839 . doi
* ^ "
Caffeine in the diet". MedlinePlus, US National Library of
Medicine. 30 April 2013. Retrieved 2 January 2015.
* ^ Rapuri PB, Gallagher JC, Kinyamu HK, Ryschon KL (November
Caffeine intake increases the rate of bone loss in elderly
women and interacts with vitamin D receptor genotypes". The American
Journal of Clinical Nutrition. 74 (5): 694–700. PMID 11684540 .
* ^ A B Maughan RJ, Griffin J (December 2003). "
and fluid balance: a review". Journal of Human Nutrition and
Dietetics. 16 (6): 411–20. PMID 19774754 . doi
* ^ Modulation of adenosine receptor expression in the proximal
tubule: a novel adaptive mechanism to regulate renal salt and water
metabolism Am. J. Physiol. Renal Physiol. 1 July 2008 295:F35-F36
* ^ Anahad O'connor (4 March 2008). "Really? The claim: caffeine
causes dehydration". New York Times. Retrieved 3 August 2009.
* ^ Armstrong LE, Casa DJ, Maresh CM, Ganio MS (July 2007).
"Caffeine, fluid-electrolyte balance, temperature regulation, and
exercise-heat tolerance". Exercise and Sport Sciences Reviews. 35 (3):
135–40. PMID 17620932 . doi :10.1097/jes.0b013e3180a02cc1 .
* ^ Tarnopolsky MA (2010). "
Caffeine and creatine use in sport".
Annals of Nutrition & Metabolism. 57 Suppl 2: 1–8. PMID 21346331 .
doi :10.1159/000322696 .
* ^ Winston AP (2005). "Neuropsychiatric effects of caffeine".
Advances in Psychiatric Treatment. 11 (6): 432–439. doi
* ^ Vilarim MM, Rocha Araujo DM, Nardi AE (August 2011). "Caffeine
challenge test and panic disorder: a systematic literature review".
Expert Review of Neurotherapeutics. 11 (8): 1185–95. PMID 21797659 .
doi :10.1586/ern.11.83 .
* ^ Smith A (September 2002). "Effects of caffeine on human
behavior". Food and Chemical Toxicology. 40 (9): 1243–55. PMID
12204388 . doi :10.1016/S0278-6915(02)00096-0 .
* ^ Bruce MS, Lader M (February 1989). "
Caffeine abstention in the
management of anxiety disorders". Psychological Medicine. 19 (1):
211–4. PMID 2727208 . doi :10.1017/S003329170001117X .
* ^ Lara DR (2010). "Caffeine, mental health, and psychiatric
disorders". Journal of Alzheimer's Disease. 20 Suppl 1: S239–48.
PMID 20164571 . doi :10.3233/JAD-2010-1378 .
* ^ Kohn R, Keller M (2015). "Chapter 34 Emotions". In Tasman A,
Kay J, Lieberman JA, First MB, Riba M. Psychiatry, 2 Volume Set.
Volume 1. New York: John Wiley & Sons. pp. 557–558. ISBN
978-1-118-84547-9 . Table 34-12...
Caffeine Intoxication – Euphoria
* ^ Hrnčiarove J, Barteček R (2017). "8. Substance Dependence".
In Hosák L, Hrdlička M, et al. Psychiatry and Pedopsychiatry.
Prague: Karolinum Press. pp. 153–154. ISBN 9788024633787 . At a high
dose, caffeine shows a euphoric effect.
* ^ Schulteis G (2010). "Brain stimulation and addiction". In Koob
GF, Le Moal M, Thompson RF. Encyclopedia of Behavioral Neuroscience.
Elsevier. p. 214. ISBN 978-0-08-091455-8 . Therefore, caffeine and
other adenosine antagonists, while weakly euphoria-like on their own,
may potentiate the positive hedonic efficacy of acute drug
intoxication and reduce the negative hedonic consequences of drug
* ^ Salerno BB, Knights EK (2010). Pharmacology for health
professionals (3rd ed.). Chatswood, N.S.W.: Elsevier Australia. p.
433. ISBN 978-0-7295-3929-6 . In contrast to the amphetamines,
caffeine does not cause euphoria, stereotyped behaviors or psychoses.
* ^ Ebenezer I (2015). Neuropsychopharmacology and Therapeutics.
John Wiley & Sons. p. 18. ISBN 978-1-118-38578-4 . However, in
contrast to other psychoactive stimulants, such as amphetamine and
cocaine, caffeine and the other methylxanthines do not produce
euphoria, stereotyped behaviors or psychotic like symptoms in large
* ^ Rang HP, Ritter JM, Flower RJ, Henderson G (2014). Rang & Dale's
Pharmacology E-Book (8th ed.). Elsevier Health Sciences. pp. 453, 594.
ISBN 978-0-7020-5497-6 . By comparison with amphetamines,
methylxanthines produce less locomotor stimulation and do not induce
euphoria, stereotyped behaviour patterns or a psychotic state, but
their effects on fatigue and mental function are similar.
Table 37.2 ... Psychomotor stimulants ... Drugs that cause
wakefulness and euphoria ... Amphetamines, cocaine, methylphenidate,
caffeine * ^ Budney AJ, Emond JA (November 2014). "Caffeine
Caffeine for youth? Time to act!". Addiction. 109 (11):
1771–2. PMID 24984891 . doi :10.1111/add.12594 . Academics and
clinicians, however, have not yet reached consensus about the
potential clinical importance of caffeine addiction (or 'use
* ^ Meredith SE, Juliano LM, Hughes JR, Griffiths RR (September
Caffeine Use Disorder: A Comprehensive Review and Research
Agenda" . Journal of
Caffeine Research. 3 (3): 114–130. PMC 3777290
. PMID 24761279 . doi :10.1089/jcr.2013.0016 .
* ^ Riba A, Tasman J, Kay JA, Lieberman MB, First MB (2014).
Psychiatry (Fourth ed.). p. 1446. ISBN 978-1-118-75336-1 .
* ^ Fishchman N, Mello N. Testing for Abuse Liability of Drugs in
Humans (PDF). 5600 Fishers Lane Rockville, MD 20857: U.S. Department
of Health and Human Services Public Health Service Alcohol, Drug
Abuse, and Mental Health Administration National Institute on Drug
Abuse. p. 179.
* ^ Nestler EJ (December 2013). "Cellular basis of memory for
addiction" . Dialogues in Clinical Neuroscience. 15 (4): 431–43. PMC
3898681 . PMID 24459410 . DESPITE THE IMPORTANCE OF NUMEROUS
PSYCHOSOCIAL FACTORS, AT ITS CORE, DRUG ADDICTION INVOLVES A
BIOLOGICAL PROCESS: the ability of repeated exposure to a drug of
abuse to induce changes in a vulnerable brain that drive the
compulsive seeking and taking of drugs, and loss of control over drug
use, that define a state of addiction. ... A large body of literature
has demonstrated that such ΔFosB induction in D1-type NAc neurons
increases an animal's sensitivity to drug as well as natural rewards
and promotes drug self-administration, presumably through a process of
* ^ Miller PM (2013). "Chapter III: Types of Addiction". Principles
of addiction comprehensive addictive behaviors and disorders (1st
ed.). Elsevier Academic Press. p. 784. ISBN 978-0-12-398361-9 .
Retrieved 11 July 2015. Astrid Nehlig and colleagues present evidence
that in animals caffeine does not trigger metabolic increases or
dopamine release in brain areas involved in reinforcement and reward.
A single photon emission computed tomography (SPECT) assessment of
brain activation in humans showed that caffeine activates regions
involved in the control of vigilance, anxiety, and cardiovascular
regulation but did not affect areas involved in reinforcement and
* ^ Nehlig A, Armspach JP, Namer IJ (2010). "SPECT assessment of
brain activation induced by caffeine: no effect on areas involved in
dependence" . Dialogues in Clinical Neuroscience. 12 (2): 255–63.
PMC 3181952 . PMID 20623930 .
Caffeine is not considered addictive,
and in animals it does not trigger metabolic increases or dopamine
release in brain areas involved in reinforcement and reward. ... these
earlier data plus the present data reflect that caffeine at doses
representing about two cups of coffee in one sitting does not activate
the circuit of dependence and reward and especially not the main
target area, the nucleus accumbens. ,, ... Therefore, caffeine appears
to be different from drugs of dependence like cocaine, amphetamine,
morphine, and nicotine, and does not fulfil the common criteria or the
scientific definitions to be considered an addictive substance.42
* ^ Temple JL (June 2009). "
Caffeine use in children: what we know,
what we have left to learn, and why we should worry" . Neuroscience
and Biobehavioral Reviews. 33 (6): 793–806. PMC 2699625 . PMID
19428492 . doi :10.1016/j.neubiorev.2009.01.001 . Through these
interactions, caffeine is able to directly potentiate dopamine
neurotransmission, thereby modulating the rewarding and addicting
properties of nervous system stimuli.
* ^ A B "
ICD-10 Version:2015". World Health Organization. 2015.
Retrieved 10 July 2015.
F15 Mental and behavioural disorders due to use of other stimulants,
including caffeine ...
.2 Dependence syndrome
A cluster of behavioural, cognitive, and physiological phenomena that
develop after repeated substance use and that typically include a
strong desire to take the drug, difficulties in controlling its use,
persisting in its use despite harmful consequences, a higher priority
given to drug use than to other activities and obligations, increased
tolerance, and sometimes a physical withdrawal state.
The dependence syndrome may be present for a specific psychoactive
substance (e.g. tobacco, alcohol, or diazepam), for a class of
substances (e.g. opioid drugs), or for a wider range of
pharmacologically different psychoactive substances.
Drug addiction * ^ Addicott MA (September 2014). "
Disorder: A Review of the Evidence and Future Implications" . Current
Addiction Reports. 1 (3): 186–192. PMC 4115451 . PMID 25089257 .
doi :10.1007/s40429-014-0024-9 .
* ^ Association American Psychiatry (2013). Diagnostic and
statistical manual of mental disorders :
DSM-5 (5th ed.). Washington :
American Psychiatric Publishing. pp. 792–795. ISBN 978-0-89042-555-8
* ^ Temple JL (June 2009). "
Caffeine use in children: what we know,
what we have left to learn, and why we should worry" . Neuroscience
and Biobehavioral Reviews. 33 (6): 793–806. PMC 2699625 . PMID
19428492 . doi :10.1016/j.neubiorev.2009.01.001 .
* ^ A B C "Information about caffeine dependence".
Caffeinedependence.org. Johns Hopkins Medicine. 9 July 2003. Archived
from the original on 23 May 2012. Retrieved 25 May 2012.
* ^ Silverman K, Evans SM, Strain EC, Griffiths RR (October 1992).
"Withdrawal syndrome after the double-blind cessation of caffeine
consumption". The New England Journal of Medicine. 327 (16):
1109–14. PMID 1528206 . doi :10.1056/NEJM199210153271601 .
* ^ Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N (2010).
Caffeine intake and dementia: systematic review and meta-analysis".
Journal of Alzheimer's Disease. 20 Suppl 1: S187–204. PMID 20182026
. doi :10.3233/JAD-2010-091387 .
* ^ Marques S, Batalha VL, Lopes LV, Outeiro TF (2011). "Modulating
Alzheimer's disease through caffeine: a putative link to epigenetics".
Journal of Alzheimer's Disease. 24 Suppl 2 (2): 161–71. PMID
21427489 . doi :10.3233/JAD-2011-110032 .
* ^ Arendash GW, Cao C (2010). "
Caffeine and coffee as therapeutics
against Alzheimer's disease". Journal of Alzheimer's Disease. 20 Suppl
1: S117–26. PMID 20182037 . doi :10.3233/JAD-2010-091249 .
* ^ Li M, Wang M, Guo W, Wang J, Sun X (March 2011). "The effect of
caffeine on intraocular pressure: a systematic review and
meta-analysis". Graefe's Archive for Clinical and Experimental
Ophthalmology = Albrecht Von Graefes Archiv Fur Klinische Und
Experimentelle Ophthalmologie. 249 (3): 435–42. PMID 20706731 . doi
* ^ Muriel P, Arauz J (July 2010). "
Coffee and liver diseases".
Fitoterapia. 81 (5): 297–305. PMID 19825397 . doi
* ^ Hackett PH (2010). "
Caffeine at high altitude: java at base
cAMP". High Altitude Medicine & Biology. 11 (1): 13–7. PMID 20367483
. doi :10.1089/ham.2009.1077 .
* ^ A B C "
Caffeine (Systemic)". MedlinePlus. 25 May 2000. Archived
from the original on 23 February 2007. Retrieved 3 August 2009.
* ^ Winston AP, Hardwick E, Jaberi N (2005). "Neuropsychiatric
effects of caffeine". Advances in Psychiatric Treatment. 11 (6):
432–439. doi :10.1192/apt.11.6.432 . Retrieved 19 December 2013.
* ^ Iancu I, Olmer A, Strous RD (2007). "Caffeinism: History,
clinical features, diagnosis, and treatment". In Smith BD, Gupta U,
Caffeine and Activation Theory: Effects on Health and
Behavior. CRC Press. pp. 331–344. ISBN 978-0-8493-7102-8 . Retrieved
15 January 2014.
American Psychiatric Association
American Psychiatric Association (1994). Diagnostic and
Statistical Manual of Mental Disorders (4th ed.). American Psychiatric
Association . ISBN 978-0-89042-062-1 .
* ^ "
Caffeine overdose". MedlinePlus. 4 April 2006. Retrieved 3
* ^ Verkhratsky A (January 2005). "Physiology and pathophysiology
of the calcium store in the endoplasmic reticulum of neurons".
Physiological Reviews. 85 (1): 201–79. PMID 15618481 . doi
* ^ Holmgren P, Nordén-Pettersson L, Ahlner J (January 2004).
Caffeine fatalities – four case reports". Forensic Science
International. 139 (1): 71–3. PMID 14687776 . doi
* ^ "FDA Consumer Advice on Powdered Pure Caffeine". FDA. Retrieved
20 August 2014.
* ^ Peters JM (1967). "Factors Affecting
Caffeine Toxicity: A
Review of the Literature". The Journal of Clinical Pharmacology and
the Journal of New Drugs. 7 (3): 131–141. doi
* ^ Murray Carpenter. "
Caffeine powder poses deadly risks". New
York Times. Retrieved 18 May 2015.
* ^ Rodopoulos N, Wisén O, Norman A (May 1995). "Caffeine
metabolism in patients with chronic liver disease". Scandinavian
Journal of Clinical and Laboratory Investigation. 55 (3): 229–42.
PMID 7638557 . doi :10.3109/00365519509089618 .
* ^ Cheston P, Smith L (11 October 2013). "Man died after
overdosing on caffeine mints". The Independent. Retrieved 13 October
* ^ Prynne M (11 October 2013). "Warning over caffeine sweets after
father dies from overdose". The Telegraph. Retrieved 13 October 2013.
* ^ Fricker M (12 October 2013). "John Jackson: Family of dad who
died from caffeine overdose after eating MINTS want them removed from
sale". Daily Mirror. Retrieved 13 October 2013.
* ^ Mackay M, Tiplady B, Scholey AB (April 2002). "Interactions
between alcohol and caffeine in relation to psychomotor speed and
accuracy". Human Psychopharmacology. 17 (3): 151–6. PMID 12404692 .
doi :10.1002/hup.371 .
* ^ A B C Liguori A, Robinson JH (July 2001). "
of alcohol-induced driving impairment". Drug and
63 (2): 123–9. PMID 11376916 . doi :10.1016/s0376-8716(00)00196-4 .
* ^ Marczinski CA, Fillmore MT (August 2003). "Dissociative
antagonistic effects of caffeine on alcohol-induced impairment of
behavioral control". Experimental and Clinical Psychopharmacology. 11
(3): 228–36. PMID 12940502 . doi :10.1037/1064-12184.108.40.206 .
* ^ Zevin S, Benowitz NL (June 1999). "Drug interactions with
tobacco smoking. An update". Clinical Pharmacokinetics. 36 (6):
425–38. PMID 10427467 . doi :10.2165/00003088-199936060-00004 .
* ^ Benowitz NL (1990). "Clinical pharmacology of caffeine". Annual
Review of Medicine. 41: 277–88. PMID 2184730 . doi
* ^ Gilmore B, Michael M (February 2011). "Treatment of acute
migraine headache". American Family Physician. 83 (3): 271–80. PMID
* ^ "World of Caffeine". World of Caffeine. 15 June 2013. Retrieved
19 December 2013.
* ^ Fisone G, Borgkvist A, Usiello A (April 2004). "
Caffeine as a
psychomotor stimulant: mechanism of action". Cellular and Molecular
Life Sciences. 61 (7–8): 857–72. PMID 15095008 . doi
* ^ "Caffeine". IUPHAR. International Union of Basic and Clinical
Pharmacology. Retrieved 2 November 2014.
* ^ Duan L, Yang J, Slaughter MM (August 2009). "Caffeine
inhibition of ionotropic glycine receptors" . The Journal of
Physiology. 587 (Pt 16): 4063–75. PMC 2756438 . PMID 19564396 .
doi :10.1113/jphysiol.2009.174797 .
* ^ A B C Ferré S (2010). "Role of the central ascending
neurotransmitter systems in the psychostimulant effects of caffeine".
Journal of Alzheimer's Disease. 20 Suppl 1: S35–49. PMID 20182056 .
doi :10.3233/JAD-2010-1400 . By targeting A1-A2A receptor heteromers
in striatal glutamatergic terminals and A1 receptors in striatal
dopaminergic terminals (presynaptic brake), caffeine induces
glutamate-dependent and glutamate-independent release of dopamine.
These presynaptic effects of caffeine are potentiated by the release
of the postsynaptic brake imposed by antagonistic interactions in the
striatal A2A-D2 and A1-D1 receptor heteromers.
* ^ A B Ferré S, Bonaventura J, Tomasi D, Navarro G, Moreno E,
Cortés A, Lluís C, Casadó V, Volkow ND (May 2016). "Allosteric
mechanisms within the adenosine A2A-dopamine D2 receptor
heterotetramer". Neuropharmacology. 104: 154–60. PMID 26051403 . doi
* ^ A B Bonaventura J, Navarro G, Casadó-Anguera V, Azdad K, Rea
W, Moreno E, Brugarolas M, Mallol J, Canela EI, Lluís C, Cortés A,
Volkow ND, Schiffmann SN, Ferré S, Casadó V (July 2015). "Allosteric
interactions between agonists and antagonists within the adenosine A2A
receptor-dopamine D2 receptor heterotetramer" . Proceedings of the
National Academy of Sciences of the United States of America. 112
(27): E3609–18. PMC 4500251 . PMID 26100888 . doi
Adenosine A2A receptor (A2AR)-dopamine D2
receptor (D2R) heteromers are key modulators of striatal neuronal
function. It has been suggested that the psychostimulant effects of
caffeine depend on its ability to block an allosteric modulation
within the A2AR-D2R heteromer, by which adenosine decreases the
affinity and intrinsic efficacy of dopamine at the D2R.
* ^ A B Ferré S (2016). "Mechanisms of the psychostimulant effects
of caffeine: implications for substance use disorders".
Psychopharmacology. 233 (10): 1963–79. PMID 26786412 . doi
:10.1007/s00213-016-4212-2 . The striatal A2A-D2 receptor heteromer
constitutes an unequivocal main pharmacological target of caffeine and
provides the main mechanisms by which caffeine potentiates the acute
and long-term effects of prototypical psychostimulants.
* ^ A B C D Ferré S (2008). "An update on the mechanisms of the
psychostimulant effects of caffeine". J. Neurochem. 105 (4):
1067–1079. PMID 18088379 . doi :10.1111/j.1471-4159.2007.05196.x .
On the other hand, our 'ventral shell of the nucleus accumbens' very
much overlaps with the striatal compartment simply described by De
Luca et al. (2007) as 'nucleus accumbens shell,' where both studies
show that caffeine does not modify the extracellular levels of
dopamine. Therefore, the results of both experimental groups are
basically the same and point to differential effects of caffeine in
different striatal subcompartments. In fact, analyzing the effects of
the intrastriatal perfusion of an A1 receptor antagonist in several
other striatal compartments showed striking differences compared with
the shell of the nucleus accumbens. Thus, A1 receptor blockade
signiﬁcantly increased the extracellular concentration of dopamine,
but not glutamate, in the core of the nucleus accumbens and in the
caudate–putamen and the effect was more pronounced in the most
medial compartments (Boryczet al. 2007). In summary, a subregional
difference in the A1 receptor-mediated control of glutamate and
dopamine release exists in the striatum ... A2A receptors play a
crucial role in the sleep-promoting effects of adenosine and the
arousal-enhancing effects of caffeine (Huang et al. 2007; Ferré et
al. 2007a). Those A2A receptors are localized in the ventrolateral
pre-optic area of the hypothalamus and their stimulation promotes
sleep by inducing
GABA release in the histaminergic tuberomammillary
nucleus, thereby inhibiting the histaminergic arousal system ...
chronic caffeine exposure counteracts both motor activation and
dopamine release in the nucleus accumbens induced by caffeine or an A1
receptor antagonist ... An additional factor that might play a
signiﬁcant role in caffeine tolerance is the signiﬁcant increase
in plasma and extracellular concentrations of adenosine with chronic
caffeine exposure ... The existence of an A1 receptor-mediated
glutamate-independent modulation of dopamine release suggested the
presence of functional A1 receptors in striatal dopaminergic
terminals. ... In the SSM, adenosine acts pre- and post-synaptically
through multiple mechanisms, which depend on heteromerization of A1
and A2A receptors among themselves and with D1 and D2 receptors,
Caffeine produces its motor and reinforcing effects by
releasing the pre- and post-synaptic brakes that adenosine imposes on
dopaminergic neurotransmission in the SSM. By releasing the
pre-synaptic brake, caffeine induces glutamate-dependent and
glutamate-independent release of dopamine.
* ^ Ribeiro JA, Sebastião AM (2010). "
Caffeine and adenosine".
Journal of Alzheimer's Disease. 20 Suppl 1: S3–15. PMID 20164566 .
doi :10.3233/JAD-2010-1379 .
* ^ Essayan DM (November 2001). "Cyclic nucleotide
phosphodiesterases". The Journal of Allergy and Clinical Immunology.
108 (5): 671–80. PMID 11692087 . doi :10.1067/mai.2001.119555 .
* ^ Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R (June
2008). "Insights into the regulation of TNF-alpha production in human
mononuclear cells: the effects of non-specific phosphodiesterase
inhibition" . Clinics. 63 (3): 321–8. PMC 2664230 . PMID 18568240
. doi :10.1590/S1807-59322008000300006 .
* ^ Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (February
Pentoxifylline inhibits TNF-alpha production from human
alveolar macrophages". American Journal of Respiratory and Critical
Care Medicine. 159 (2): 508–11. PMID 9927365 . doi
* ^ A B Peters-Golden M, Canetti C, Mancuso P, Coffey MJ (January
2005). "Leukotrienes: underappreciated mediators of innate immune
responses". Journal of Immunology. 174 (2): 589–94. PMID 15634873 .
doi :10.4049/jimmunol.174.2.589 .
* ^ Arnaud, M. J. (2011). "
Natural Methylxanthines in Animal and Man. In: Methylxanthines.".
Handbook of Experimental Pharmacology. 200. doi
* ^ Liguori A, Hughes JR, Grass JA (November 1997). "Absorption and
subjective effects of caffeine from coffee, cola and capsules".
Pharmacology, Biochemistry, and Behavior. 58 (3): 721–6. PMID
9329065 . doi :10.1016/S0091-3057(97)00003-8 .
* ^ Newton R, Broughton LJ, Lind MJ, Morrison PJ, Rogers HJ,
Bradbrook ID (1981). "Plasma and salivary pharmacokinetics of caffeine
in man". European Journal of Clinical Pharmacology. 21 (1): 45–52.
PMID 7333346 . doi :10.1007/BF00609587 .
* ^ Graham JR (June 1954). "Rectal use of ergotamine tartrate and
caffeine alkaloid for the relief of migraine". The New England Journal
of Medicine. 250 (22): 936–8. PMID 13165929 . doi
* ^ Brødbaek HB, Damkier P (May 2007). "". Ugeskrift for Laeger
(in Danish). 169 (22): 2122–3. PMID 17553397 .
* ^ Teekachunhatean S, Tosri N, Rojanasthien N, Srichairatanakool
S, Sangdee C (8 January 2013). "
a Single Administration of
Coffee Enema versus Oral
in Healthy Male Subjects" . ISRN Pharmacology. Hindawi Publishing
Corporation. 2013 (147238): 147238. PMC 3603218 . PMID 23533801 .
doi :10.1155/2013/147238 .
* ^ "Drug Interaction:
Caffeine Oral and
Medscape Multi-Drug Interaction Checker.
* ^ "Caffeine". The Pharmacogenetics and Pharmacogenomics Knowledge
Base. Retrieved 25 October 2010.
* ^ Verbeeck RK (December 2008). "
Pharmacokinetics and dosage
adjustment in patients with hepatic dysfunction". European Journal of
Clinical Pharmacology. 64 (12): 1147–61. PMID 18762933 . doi
* ^ Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN,
Berndt SI, Boerwinkle E, Chanock S, Chatterjee N, Couper D, Curhan G,
Heiss G, Hu FB, Hunter DJ, Jacobs K, Jensen MK, Kraft P, Landi MT,
Nettleton JA, Purdue MP, Rajaraman P, Rimm EB, Rose LM, Rothman N,
Silverman D, Stolzenberg-Solomon R, Subar A, Yeager M, Chasman DI, van
Dam RM, Caporaso NE (April 2011). Gibson G, ed. "Genome-wide
meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as
determinants of habitual caffeine consumption" . PLoS Genetics. 7 (4):
e1002033. PMC 3071630 . PMID 21490707 . doi
* ^ A B Susan Budavari, ed. (1996). The Merck Index (12th ed.).
Whitehouse Station, NJ: Merck & Co., Inc. p. 1674.
* ^ This is the pKa for protonated caffeine, given as a range of
values included in Brittain HG, Prankerd RJ (2007). Profiles of Drug
Substances, Excipients and Related Methodology, volume 33: Critical
Compilation of pKa Values for Pharmaceutical Substances. Academic
Press. p. 15. ISBN 978-0-12-260833-9 . Retrieved 15 January 2014.
* ^ Klosterman L (2006). The Facts About
Benchmark Books (NY). p. 43. ISBN 0-7614-2242-0 .
* ^ Vallombroso T (2001). Organic Chemistry Pearls of Wisdom.
Boston Medical Publishing Corp. p. 43. ISBN 978-1-58409-016-8 .
* ^ Keskineva N. "Chemistry of Caffeine" (PDF). Chemistry
Department, East Stroudsburg University. Archived from the original
(PDF) on 2 January 2014. Retrieved 2 January 2014.
* ^ "
Caffeine biosynthesis". The
Enzyme Database. Trinity College
Dublin. Retrieved 24 September 2011.
* ^ "MetaCyc Pathway: caffeine biosynthesis I". MetaCyc database.
SRI International . Retrieved 12 July 2017.
* ^ A B Temple NJ, Wilson T (2003).
Beverages in Nutrition and
Health. Totowa, NJ: Humana Press. p. 172. ISBN 978-1-58829-173-8 .
* ^ A B US patent 2785162, Swidinsky J, Baizer MM, "Process for the
formylation of a 5-nitrouracil", published 12 March 1957, assigned to
New York Quinine and Chemical Works, Inc.
* ^ Denoeud F, Carretero-Paulet L, Dereeper A, Droc G, Guyot R,
Pietrella M, Zheng C, Alberti A, Anthony F, Aprea G, Aury JM, Bento P,
Bernard M, Bocs S, Campa C, Cenci A, Combes MC, Crouzillat D, Da Silva
C, Daddiego L, De Bellis F, Dussert S, Garsmeur O, Gayraud T, Guignon
V, Jahn K, Jamilloux V, Joët T, Labadie K, Lan T, Leclercq J,
Lepelley M, Leroy T, Li LT, Librado P, Lopez L, Muñoz A, Noel B,
Pallavicini A, Perrotta G, Poncet V, Pot D, Rigoreau M, Rouard M,
Rozas J, Tranchant-Dubreuil C, VanBuren R, Zhang Q, Andrade AC, Argout
X, Bertrand B, de Kochko A, Graziosi G, Henry RJ, Ming R, Nagai C,
Rounsley S, Sankoff D, Giuliano G, Albert VA, Wincker P, Lashermes P
(September 2014). "The coffee genome provides insight into the
convergent evolution of caffeine biosynthesis". Science. 345 (6201):
1181–4. PMID 25190796 . doi :10.1126/science.1255274 .
* ^ Huang R, O'Donnell AJ, Barboline JJ, Barkman TJ (September
Convergent evolution of caffeine in plants by co-option of
exapted ancestral enzymes" . Proceedings of the National Academy of
Sciences of the United States of America. 113 (38): 10613–8. PMC
5035902 . PMID 27638206 . doi :10.1073/pnas.1602575113 .
* ^ Williams R (September 21, 2016). "How Plants Evolved Different
Ways to Make Caffeine".
* ^ Zajac MA, Zakrzewski AG, Kowal MG, Narayan S (2003). "A Novel
Caffeine Synthesis from Uracil" (PDF). Synthetic
Communications. 33 (19): 3291–3297. doi :10.1081/SCC-120023986 .
* ^ Simon Tilling. "Crystalline Caffeine".
Bristol University .
Retrieved 3 August 2009.
* ^ A B C Senese F (20 September 2005). "How is coffee
decaffeinated?". General Chemistry Online. Retrieved 3 August 2009.
* ^ McCusker RR, Fuehrlein B, Goldberger BA, Gold MS, Cone EJ
(October 2006). "
Caffeine content of decaffeinated coffee". Journal of
Analytical Toxicology. 30 (8): 611–3. PMID 17132260 . doi
:10.1093/jat/30.8.611 . Lay summary – University of Florida News.
* ^ Baselt R (2017). Disposition of Toxic Drugs and Chemicals in
Man (11th ed.). Seal Beach, CA: Biomedical Publications. pp. 335–8.
ISBN 978-0-692-77499-1 .
* ^ Seale TW, Abla KA, Shamim MT, Carney JM, Daly JW (1988).
"3,7-Dimethyl-1-propargylxanthine: a potent and selective in vivo
antagonist of adenosine analogs". Life Sciences. 43 (21): 1671–84.
PMID 3193854 . doi :10.1016/0024-3205(88)90478-x .
* ^ Kennerly J (22 September 1995). "N Substituted Xanthines: A
Caffeine Analog Information File". Retrieved 6 November 2015.
* ^ Müller CE, Jacobson KA (19 August 2010). Fredholm BB, ed.
Xanthines as adenosine receptor antagonists" . Handbook of
Experimental Pharmacology. Handbook of Experimental Pharmacology.
Springer Berlin Heidelberg. 200 (200): 151–99. PMC 3882893 . PMID
20859796 . doi :10.1007/978-3-642-13443-2_6 .
* ^ "Which Plants Contain Caffeine?". medscape.com.
* ^ For more information, see Alejandro Lopez-Ortiz. "Frequently
Asked Questions about
Coffee and Caffeine".
* ^ Nathanson JA (October 1984). "
Caffeine and related
methylxanthines: possible naturally occurring pesticides". Science.
226 (4671): 184–7. PMID 6207592 . doi :10.1126/science.6207592 .
* ^ Frischknecht PM, Ulmer-Dufek J, Baumann TW (1986). "Purine
alkaloid formation in buds and developing leaflets of
Expression of an optimal defence strategy?". Phytochemistry. 25 (3):
613–6. doi :10.1016/0031-9422(86)88009-8 .
* ^ Baumann TW (1984). "
Metabolism and excretion of caffeine during
Coffea arabica L". Plant and Cell Physiology. 25 (8):
* ^ van Breda, Shane V.; van der Merwe, Chris F.; Robbertse,
Hannes; Apostolides, Zeno (10 November 2012). "Immunohistochemical
localization of caffeine in young
Camellia sinensis (L.) O. Kuntze
(tea) leaves". Planta. 237 (3): 849–858. doi
* ^ A B Wright GA, Baker DD, Palmer MJ, Stabler D, Mustard JA,
Power EF, Borland AM, Stevenson PC (March 2013). "
Caffeine in floral
nectar enhances a pollinator\'s memory of reward" . Science. 339
Bibcode :2013Sci...339.1202W. PMC 4521368 . PMID
23471406 . doi :10.1126/science.1228806 .
* ^ Balentine DA, Harbowy ME, Graham HN (1998). G Spiller, ed. Tea:
the Plant and its Manufacture; Chemistry and Consumption of the
* ^ "
Caffeine Content of Food and Drugs". Nutrition Action Health
Center for Science in the Public Interest
Center for Science in the Public Interest . 1996. Archived
from the original on 14 June 2007. Retrieved 3 August 2009.
* ^ A B "
Caffeine Content of Beverages, Foods, & Medications". The
Erowid . 7 July 2006. Retrieved 3 August 2009.
* ^ "
Caffeine Content of Drinks".
Caffeine Informer. Retrieved 8
* ^ A B Chin JM, Merves ML, Goldberger BA, Sampson-Cone A, Cone EJ
(October 2008). "
Caffeine content of brewed teas". Journal of
Analytical Toxicology. 32 (8): 702–4. PMID 19007524 . doi
* ^ A B Richardson B (2009). "Too Easy to be True. De-bunking the
Decaffeination Myth". Elmwood Inn. Retrieved 12 January 2012.
* ^ "Traditional Yerba Mate in Biodegradable Bag". Guayaki Yerba
Mate. Retrieved 17 July 2010.
* ^ Matissek R (1997). "Evaluation of xanthine derivatives in
chocolate: nutritional and chemical aspects". European Food Research
and Technology. 205 (3): 175–84. doi :10.1007/s002170050148 . INIST
* ^ A B "Caffeine". International
Coffee Organization. Archived
from the original on 27 March 2009. Retrieved 1 August 2009.
* ^ A B "
Caffeine FAQ: Does dark roast coffee have less
caffeine than light roast?". Retrieved 2 August 2009.
* ^ A B "All About Coffee:
Caffeine Level". Jeremiah's Pick Coffee
Co. Archived from the original on 18 March 2008. Retrieved 3 August
* ^ A B Hicks MB, Hsieh YH, Bell LN (1996). "
Tea preparation and
its influence on methylxanthine concentration". Food Research
International. 29 (3–4): 325–330. doi
* ^ "Nutrition and healthy eating". Mayo Clinic. Retrieved 18
* ^ Bempong DK, Houghton PJ, Steadman K (1993). "The xanthine
content of guarana and its preparations". Int J Pharmacog. 31 (3):
175–181. ISSN 0925-1618 . doi :10.3109/13880209309082937 .
* ^ Smit HJ, Gaffan EA, Rogers PJ (November 2004). "Methylxanthines
are the psycho-pharmacologically active constituents of chocolate".
Psychopharmacology. 176 (3–4): 412–9. PMID 15549276 . doi
* ^ Weinberg BA, Bealer BK (2001). The World of caffeine: The
Science and Culture of the World\'s Most Popular Drug. Routledge. p.
195. ISBN 978-0-415-92723-9 . Retrieved 15 January 2014.
* ^ "LeBron James Shills for Sheets
Caffeine Strips, a Bad Idea for
Teens, Experts Say". Abcnews.go.com. ABC News. 10 June 2011. Retrieved
25 May 2012.
* ^ Nancy Shute (15 April 2007). "Over The Limit:Americans young
and old crave high-octane fuel, and doctors are jittery". US News and
World Reports. Archived from the original on 8 January 2014.
* ^ "F.D.A. Inquiry Leads Wrigley to Halt \'Energy Gum\' Sales".
New York Times. Associated Press. 8 May 2013. Retrieved 9 May 2013.
* ^ "Some Common Questions". Eagle Energy. Retrieved 2017-05-22.
* ^ "2012 - Breathable Foods, Inc. 3/5/12". www.fda.gov. Retrieved
* ^ "Food Additives & Ingredients > Caffeinated Alcoholic
Beverages". fda.gov. Food and Drug Administration. 17 November 2010.
Retrieved 24 January 2014.
* ^ Evans JC (1992).
Tea in China: The History of China's National
Drink. Greenwood Press. p. 2. ISBN 978-0-313-28049-8 .
* ^ Yu L (1995). The Classic of Tea: Origins & Rituals. Ecco Pr.
ISBN 978-0-88001-416-8 .
* ^ Weinberg BA, Bealer BK (2001). The World of Caffeine: The
Science and Culture of the World's Most Popular Drug. Routledge. pp.
3–4. ISBN 978-0-415-92723-9 .
* ^ Meyers H (7 March 2005). ""Suave Molecules of Mocha" –
Coffee, Chemistry, and Civilization". New Partisan. Archived from the
original on 9 March 2005. Retrieved 3 February 2007.
* ^ A B Fairbanks CH (2004). "The function of black drink among the
Creeks". In Hudson MC . Black Drink. University of Georgia Press. p.
123. ISBN 978-0-8203-2696-2 .
* ^ Crown PL, Emerson TE, Gu J, Hurst WJ, Pauketat TR, Ward T
(August 2012). "Ritual Black Drink consumption at Cahokia" .
Proceedings of the National Academy of Sciences of the United States
of America. 109 (35): 13944–9. PMC 3435207 . PMID 22869743 . doi
* ^ Runge FF (1820). Neueste phytochemische Entdeckungen zur
Begründung einer wissenschaftlichen Phytochemie . Berlin: G. Reimer.
pp. 144–159. Retrieved 8 January 2014.
* ^ In 1819, Runge was invited to show Goethe how belladonna caused
dilation of the pupil, which Runge did, using a cat as an experimental
subject. Goethe was so impressed with the demonstration that: "Nachdem
Goethe mir seine größte Zufriedenheit sowol über die Erzählung des
durch scheinbaren schwarzen Staar Geretteten, wie auch über das
andere ausgesprochen, übergab er mir noch eine Schachtel mit
Kaffeebohnen, die ein Grieche ihm als etwas Vorzügliches gesandt.
"Auch diese können Sie zu Ihren Untersuchungen brauchen," sagte
Goethe. Er hatte recht; denn bald darauf entdeckte ich darin das,
wegen seines großen Stickstoffgehaltes so berühmt gewordene
Coffein." (After Goethe had expressed to me his greatest satisfaction
regarding the account of the man rescued by apparent "black star"
as well as the other, he handed me a carton of coffee beans, which a
Greek had sent him as a delicacy. "You can also use these in your
investigations," said Goethe. He was right; for soon thereafter I
discovered therein caffeine, which became so famous on account of its
high nitrogen content.)
This account appeared in Runge's book Hauswirtschaftlichen Briefen
(Domestic Letters ) of 1866. It was reprinted in: Johann Wolfgang von
Goethe with F.W. von Biedermann, ed., Goethes Gespräche, vol. 10:
Nachträge, 1755–1832 (Leipzig, (Germany): F.W. v. Biedermann,
1896), pages 89–96; see especially page 95. * ^ Weinberg BA,
Bealer BK (2001). The World of Caffeine: The Science and Culture of
the World's Most Popular Drug. Routledge. pp. xvii–xxi. ISBN
* ^ Berzelius, Jöns Jakob (1825). "Jahres-Bericht über die
Fortschritte der physischen Wissenschaften von Jacob Berzelius" (in
German). 4: 180. From page 180: "Caféin ist eine Materie im Kaffee,
die zu gleicher Zeit, 1821, von
Robiquet und Pelletier und Caventou
entdekt wurde, von denen aber keine etwas darüber im Drucke bekannt
Caffeine is a material in coffee, which was discovered at
the same time, 1821, by
Robiquet and Pelletier and Caventou, by whom
however nothing was made known about it in the press.)
* ^ Berzelius JJ (1828). Jahres-Bericht über die Fortschritte der
physischen Wissenschaften von Jacob Berzelius (in German). 7. p. 270.
From page 270: "Es darf indessen hierbei nicht unerwähnt bleiben,
dass Runge (in seinen phytochemischen Entdeckungen 1820, p. 146-7.)
dieselbe Methode angegeben, und das Caffein unter dem Namen Caffeebase
ein Jahr eher beschrieben hat, als Robiquet, dem die Entdeckung dieser
Substanz gewöhnlich zugeschrieben wird, in einer Zusammenkunft der
Societé de Pharmacie in Paris die erste mündliche Mittheilung
darüber gab." (However, at this point, it should not remain
unmentioned that Runge (in his Phytochemical Discoveries, 1820, pages
146–147) specified the same method and described caffeine under the
name Caffeebase a year earlier than Robiquet, to whom the discovery of
this substance is usually attributed, having made the first oral
announcement about it at a meeting of the Pharmacy Society in Paris.)
* ^ Pelletier, Pierre Joseph (1822). "Cafeine". Dictionnaire de
Médecine (in French). 4. Paris: Béchet Jeune. pp. 35–36. Retrieved
3 March 2011.
* ^ Robiquet, Pierre Jean (1823). "Café". Dictionnaire
Technologique, ou Nouveau Dictionnaire Universel des Arts et Métiers
(in French). 4. Paris: Thomine et Fortic. pp. 50–61. Retrieved 3
* ^ Dumas; Pelletier (1823). "Recherches sur la composition
élémentaire et sur quelques propriétés caractéristiques des bases
salifiables organiques" . Annales de Chimie et de Physique (in
French). 24: 163–191.
* ^ Oudry M (1827). "Note sur la Théine". Nouvelle bibliothèque
médicale (in French). 1: 477–479.
* ^ Mulder, G. J. (1838). "Ueber Theïn und Caffeïn" . Journal
für Praktische Chemie. 15: 280–284. doi :10.1002/prac.18380150124 .
* ^ Jobst, Carl (1838). "Thein identisch mit Caffein" . Liebig's
Annalen der Chemie und Pharmacie. 25: 63–66. doi
* ^ Fischer began his studies of caffeine in 1881; however,
understanding of the molecule's structure long eluded him. In 1895 he
synthesized caffeine, but only in 1897 did he finally fully determine
its molecular structure.
* Fischer E (1881). "Ueber das Caffeïn" . Berichte der Deutschen
chemischen Gesellschaft zu Berlin (in German). 14: 637–644. doi
* Fischer E (1881). "Ueber das Caffeïn. Zweite Mitteilung" .
Berichte der Deutschen chemischen Gesellschaft zu Berlin (in German).
14 (2): 1905–1915. doi :10.1002/cber.18810140283 .
* Fischer E (1882). "Ueber das Caffeïn. Dritte Mitteilung" .
Berichte der Deutschen chemischen Gesellschaft zu Berlin (in German).
15: 29–33. doi :10.1002/cber.18820150108 .
* Fischer E, Ach L (1895). "Synthese des Caffeïns" . Berichte der
Deutschen chemischen Gesellschaft zu Berlin (in German). 28 (3):
3135–3143. doi :10.1002/cber.189502803156 .
* Fischer E (1897). "Ueber die Constitution des Caffeïns, Xanthins,
Hypoxanthins und verwandter Basen" . Berichte der Deutschen chemischen
Gesellschaft zu Berlin (in German). 30: 549–559. doi
* ^ Hj. Théel (1902). "Nobel Prize Presentation Speech".
Retrieved 3 August 2009.
* ^ Brown DW (2004). A new introduction to Islam. Chichester, West
Sussex: Wiley-Blackwell. pp. 149–51. ISBN 978-1-4051-5807-7 .
* ^ Ágoston, Gábor; Masters, Bruce (2009). Encyclopedia of the
Ottoman Empire. p. 138. ISBN 978-1-4381-1025-7 .
* ^ Hopkins K (24 March 2006). "Food Stories: The Sultan\'s Coffee
Prohibition". Accidental Hedonist. Archived from the original on 20
November 2012. Retrieved 3 January 2010.
* ^ "By the King. A PROCLAMATION FOR THE Suppression of
Coffee-Houses". Retrieved 18 March 2012.
* ^ Pendergrast 2001 , p. 13
* ^ Pendergrast 2001 , p. 11
* ^ Bersten 1999 , p. 53
* ^ Benjamin LT, Rogers AM, Rosenbaum A (January 1991). "Coca-Cola,
caffeine, and mental deficiency: Harry Hollingworth and the
Chattanooga trial of 1911". Journal of the History of the Behavioral
Sciences. 27 (1): 42–55. PMID 2010614 . doi
* ^ "The Rise and Fall of
Cocaine Cola". Lewrockwell.com. Retrieved
25 May 2012.
* ^ "CFR – Code of Federal Regulations Title 21". U.S. Food and
Drug Administration. 21 August 2015. Retrieved 23 November 2015.
* ^ Sanner A (19 July 2014). "Sudden death of Ohio teen highlights
dangers of caffeine powder". The Globe and Mail. Columbus, Ohio:
Phillip Crawley. The Associated Press. Retrieved 23 November 2015.
* ^ Reissig CJ, Strain EC, Griffiths RR (January 2009).
"Caffeinated energy drinks—a growing problem" . Drug and Alcohol
Dependence. 99 (1–3): 1–10. PMC 2735818 . PMID 18809264 . doi
:10.1016/j.drugalcdep.2008.08.001 . Lay summary – ScienceDaily (25
* ^ Geoffrey Burchfield (1997). Meredith Hopes, ed. "What\'s your
poison: caffeine". Australian Broadcasting Corporation. Retrieved 15
* ^ "Mormonism in the News: Getting It Right August 29". The Church
of Jesus Christ of Latter-Day Saints. 2012. Retrieved 17 April 2016.
* ^ Juan Eduardo Campo (1 January 2009). Encyclopedia of Islam.
Infobase Publishing. p. 154. ISBN 978-1-4381-2696-8 . Retrieved 1
* ^ Daniel W. Brown (24 August 2011). A New Introduction to Islam.
John Wiley & Sons. p. 149. ISBN 978-1-4443-5772-1 .
* ^ "Newly Discovered Bacteria Lives on Caffeine".
Blogs.scientificamerican.com. 24 May 2011. Retrieved 19 December 2013.
* ^ Paul L. "Why
Caffeine is Toxic to Birds". HotSpot for Birds.
Advin Systems. Retrieved 29 February 2012.
* ^ "Caffeine". Retrieved 12 September 2014.
* ^ Noever R, Cronise J, Relwani RA (29 April 1995). "Using
spider-web patterns to determine toxicity". NASA Tech Briefs. New
Scientist magazine. 19 (4): 82.
* ^ Arnaud MJ (2011). "
Pharmacokinetics and metabolism of natural
methylxanthines in animal and man". Handbook of Experimental
Pharmacology. Handbook of Experimental Pharmacology. 200 (200):
33–91. ISBN 978-3-642-13442-5 . PMID 20859793 . doi
* ^ Thomas J, Chen Q, Howes N (August 1997). "Chromosome doubling
of haploids of common wheat with caffeine". Genome. 40 (4): 552–8.
PMID 18464846 . doi :10.1139/g97-072 .
* Bersten I (1999). Coffee, Sex & Health: A history of anti-coffee
crusaders and sexual hysteria. Sydney: Helian Books. ISBN
* Pendergrast M (2001) . Uncommon Grounds: The History of
How It Transformed Our World. London: Texere. ISBN 1-58799-088-1 .
Wikimedia Commons has media related to CAFFEINE .
Wikinews has related news: ALZHEIMER\\'S DISEASE REVERSED IN MICE
* GMD MS Spectrum
* The Consumers Union Report on Licit and Illicit Drugs,
Caffeine-Part 1 Part 2
* Caffeine: ChemSub Online
The Periodic Table of Videos (University of
Caffeine International Chemical Safety Cards
Mayo Clinic staff (3 October 2009). "
Caffeine content for coffee,
tea, soda and more".
Mayo Clinic . Retrieved 8 November 2010.
* Fair trade